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CHAPTER I 
 
 
INTRODUCTION 
 
 
Goal of the Research Project 
 Activation of coagulation factor IX, a protein found in blood, is a pivotal reaction 
in the formation and maintenance of a fibrin clot at a site of vascular injury. Hereditary 
deficiency of factor IX causes the severe bleeding disorder known as hemophilia B. 
Factor IX must be activated to participate in coagulation. This process is mediated by two 
plasma proteases, factor VIIa and factor XIa. While a considerable amount of information 
is available concerning factor IX activation by factor VIIa, relatively little is known about 
the factor XIa-mediated reaction. Recently, factor IX and factor XIa have been identified 
as contributors to pathologic blood coagulation in such disorders as arterial and venous 
thrombosis and disseminated intravascular coagulation, and there is substantial interest in 
therapeutic inhibition of these proteins. The goals of this project were to investigate the 
mechanism by which factor XIa activates factor IX, and to study the process by which 
factor XIa is generated from its inactive precursor, factor XI. The work resulted in the 
publication of two manuscripts with one manuscript in press and another in preparation: 
Smith SB, Verhamme IM, Sun M-F, Bock PE, Gailani D.  Characterization of novel 
forms of coagulation factor XIa: Independence of factor XIa subunits in factor IX 
activation. J. Biol. Chem. 2008;283:6696-6705. 
 
Smith SB, Gailani D: Update on the physiology and pathology of factor IX activation 
by factor XIa. Expert Review of Hematology 2008;1:87-98. 
 
Gailani D, Smith SB: Structural and functional features of factor XI. - J. Thromb. 
Haemost. (In press). 
 
Smith SB, Agah S, Bajaj SP, Gailani D. An Analysis of Cleavage of the factor IX 
Activation Sites by Factor XIa. (Manuscript in preparation) 
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Introduction to Blood Coagulation 
 Bleeding is terminated at sites of injury by the process of blood coagulation, 
which involves the formation of a fibrin and platelet rich clot over a site of vascular 
damage. Clot formation is mediated by the interactions of a group of proteins (clotting 
factors) found in solution in blood plasma with specific receptors found on platelets and 
at the site of vascular injury (Davie et al., 1991; Mann, 1999; Furie and Furie, 2009). A 
central concept underlying blood coagulation is that the blood borne coagulation factors, 
many  of  which  are  the  zymogens  of  serine  proteases,  are  incorporated  into  a  self- 
amplifying   proteolytic   chain   reaction   (Figure I-1),   only  when  presented  with  the 
 
 
 
Figure I-1. Models of fibrin generation. (A) Cascade model. Fibrin generation is initiated by 
a series of proteolyic reactions involving plasma proteases (black lettering). Activated factors 
have a lower case "a" following the Roman numeral. Coagulation is triggered by activation of 
factor (F) XII to FXIIa on a charged surface or by exposure of FVIIa to tissue factor (TF). (B) 
Current Model. TF binds to FVIIa at a site of vascular injury. The FVIIa/TF complex activates 
FX, which converts prothrombin to -thrombin to initiate fibrin formation. FVIIa/TF is 
inhibited by tissue factor pathway inhibitor (TFPI) in a FXa-dependent manner. Sustained FX 
activation requires FIXa (IXa), which is activated by FVIIa/TF or FXIa. Once FVIIa/TF is 
inhibited, FXIa may continue to activate FIX to ensure adequate FX and prothrombin 
activation. In this model, factor XI is activated by -thrombin or factor XIIa. For both models, 
cofactors are shown in black circles. FV and FVIII are activated by -thrombin, and enhance 
the catalytic efficiency of FXa and FIXa, respectively. Black and white arrows indicate 
protease-mediated reactions, with white arrows indicating reactions involved in factor XI 
activation and factor XIa activity. The red arrow indicates an inhibitory process. 
A B 
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appropriate triggering molecules that are exposed by vascular damage.  Thus stimulated, 
coagulation factors in association with the triggering molecules introduced to blood 
during injury, catalyze the conversion of soluble fibrinogen into insoluble fibrin and 
contribute to the activation of platelets. Because inappropriate or excessive clot formation 
can occlude blood vessels, a delicate balance exists between damage recognition, and clot 
formation, maintenance, and breakdown. 
 To facilitate the formation of a blood clot, as well as to localize clot formation to 
the site of injury, vertebrates have evolved an elaborate, multi-step vascular damage 
recognition mechanism that was originally termed the coagulation cascade (Figure I-
1A), (Macfarlane 1964; Davie and Ratnoff 1964). First proposed in 1964, the cascade or 
waterfall model provided a conceptual framework for incorporating known plasma 
coagulation factors into a fibrin generating mechanism. Most coagulation factors were 
assigned Roman numerals by an international committee between 1957 and 1963. The 
recurring theme in this model is that a plasma protease activates the next zymogen (the 
inactive precursor of a protease) in the cascade, to propagate the process. A limitation of 
this model is that it is not easy to reconcile with the bleeding patterns associated with 
congenital deficiencies of the individual clotting factors. For example, factor IX 
deficiency is associated with a severe hemorrhagic phenotype, while factor XII 
deficiency is not associated with excessive bleeding, despite the fact they both appear to 
be components of a linear pathway of reactions that trigger clot formation. 
 Over the past forty years, the coagulation factors have been purified from plasma, 
their genes and cDNAs have been cloned, and three-dimensional structures are available 
for most of them. With advances in our understanding of structure-function relationships 
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for these molecules, newer models of fibrin formation and maintenance have been 
proposed that have replaced the original cascade, and emphasize reactions that are more 
likely to occur in vivo (Figure I-1B) (Broze et al., 1990; Gailani and Broze, 1991; Davie 
et al., 1991). It is the goal of this thesis proposal to investigate the process by which the 
plasma coagulation factor, factor XI, is converted to an active protease (factor XIa), and 
the mechanism by which factor XIa contributes to coagulation through proteolytic 
activation of factor IX. 
 
Coagulation Proteases 
 The coagulation factors depicted in the schemes in Figure I fall into three general 
categories. Fibrinogen (factor I) is converted to fibrin, the structural component of the 
clot.  Factors II (prothrombin), VII, IX, X, XI, XII and prekallikrein (PK) are the 
zymogens of serine proteases.  Finally, tissue factor (TF - also considered factor III), 
factors Va and VIIIa, and high molecular weight kininogen (HMWK) are protein 
cofactors that facilitate assembly of coagulation proteases on surfaces (Davie et al., 1991; 
Furie and Furie, 2009). The work in this thesis primarily is concerned with the activation 
and activity of certain coagulation proteases. All coagulation proteases contain a C-
terminal catalytic domain that is homologous to the digestive enzyme trypsin, and a series 
of N-terminal auxiliary domains homologous to portions of other proteins that have been 
added to the catalytic domain by the processes of gene duplication and translocation 
(Tordai et al., 1999; Jiang and Doolittle, 2003; Davidson et al., 2003; Ponczek et al., 
2008) (Figure I-2). Auxiliary  domains  generally  contain  one or more binding sites that 
determine  or  modify  the   specificity  of  enzyme  binding  to  substrates,  cofactors, and 
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Figure I-2. Schematic diagram of coagulation protease domain structures.  Each box 
represents the amino acids encoded by a single exon in the gene for the protein.  Signal 
peptides (yellow) and the Pro portion of the Pro-Gla domains (red) are removed prior to 
secretion from hepatoctyes. The Gla domains undergo post-translational modifications that 
facilitate Ca2+ binding.  The black arrows indicate the locations where protease zymogens 
must be cleaved to generate the active protease.  Note that the apple domains of factor XI and 
prekallikrein are each encoded by two exons. Adapted from Furie and Furie, 2009. 
  
surfaces. These auxiliary domains embody the evolutionary pressure that drove the 
development of specificity of each clotting factor and, thus, its contribution to 
hemostasis.  
 
The Catalytic Domains of Trypsin and Coagulation Proteases  
 Vertebrates share a common complement of genes encoding peptidases, 
indicating that the expansion of the common peptidase families occurred prior to the 
appearance of the vertebrate lineage (Page and DiCera, 2008). Of these families, the 
trypsin-like serine peptidases are the largest homologous group. The catalytic domain of 
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each coagulation protease belongs to the S1A trypsin family of peptidases that cleave on 
the C-terminal side of amino acids with a positively charged side chain such as Arginine 
or Lysine. Chymotrypsinogen, which cleaves after large hydrophobic residues (Phe, Trp, 
and Tyr), was the first member of this family to be crystallized, and residues of the 
catalytic domains of trypsin-like enzymes are conventionally numbered using the 
chymotrypsinogen numbering system (Bode et al., 1989). When describing catalytic 
domain residues in this thesis, we will hereafter use the chymotrypsin numbering system 
unless otherwise indicated.  
 Trypsin is a "serine protease" because it contains an unusually reactive, basic 
serine residue (Ser195) in its active site (Blow, 1990). Trypsin-like serine proteases 
contain a catalytic triad consisting of Asp102 and His57, in addition to Ser195 (Figure I-
3). Binding of a substrate to the enzyme orients the catalytic triad such that Asp102 
stabilizes an electropositive form of His57, which in turn abstracts a proton from Ser195, 
rendering that residue nucleophilic. Nucleophilic Ser195 attacks the carbonyl carbon of  a 
properly positioned peptide bond, forming an oxyanion tetrahedral intermediate that is 
stabilized  by  backbone  N atoms of Gly193 and Ser195. This interaction takes place in an 
 
Figure I-3. The active site of a trypsin-
like serine protease. The diagram shows 
the amino acids of the active site (black) 
interacting with a hypothetical substrate 
(blue). Hydrogen bonds between 
substrate and enzyme are in red. The 
substrate P1 Arg side chain forms 
hydrogen bonds with Asp189 in the S1 
specificity pocket. The catalytic triad 
Asp102, His57 and Ser195 is shown at the 
top, with Gly193 on the right. The 
backbone amido groups of Ser195 and 
Gly193 form part of the oxyanion hole 
structure. Chymotrypsinogen numbering 
used throughout. (After Craik and 
Perona, 1995)  
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area of the enzyme active site referred to as the oxyanion hole (Figure I-3), and it 
stabilizes the transition state of the substrate by 1.5 to 3 kcal/mole (Stryer, 1995; Page 
and DiCera, 2008). The oxyanion hole also stabilizes a second tetrahedral intermediate in 
which water displaces the polypeptide fragment generated by bond cleavage. Zymogens 
of most serine proteases related to chymotrypsinogen, including all coagulation proteases, 
must be cleaved in order to generate an active enzyme. Cleavage occurs between the 
residues corresponding to Arg15 and Ile16 in chymotrypsinogen numbering. The cleavage 
generates a new N-terminus (residue 16) that forms an electrostatic interaction with 
Asp194, resulting in formation of the oxyanion hole and substrate-binding site (Bode et 
al., 1976; Fehlhammer et al., 1977).  Formation of the salt bridge between residue 16 and 
Asp194 is a defining feature of an active serine protease. 
 The substrate specificity of trypsin, as well as other degradative enzymes, is 
primarily driven by interactions involving amino acids flanking the cleavage site on the 
substrate, and residues surrounding the catalytic triad on the enzyme. In enzymatic 
nomenclature, substrate amino acids flanking the cleavage site are designated P, and the 
amino acids in the activating enzyme that interact with them are designated S (Schechter 
and Berger, 1967).  Numbers following P designate the amino acid position on the 
substrate relative to the scissile bond. By convention, residues on the substrate extending 
from the scissile bond toward the N-terminus are P1, P2, P3…Pn (Figure I-3). The 
complementary sites on the activating enzyme that engage these residues are designated 
S1, S2, S3…Sn. On the C-terminus of the scissile bond, substrate residues are numbered 
P1, P2, P3 with the complementary protease residues numbered S1, S2, and S3. 
Interactions of these residues, particularly the P1 residue, which is arginine or lysine in 
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most substrates of trypsin-like enzymes, are important for the docking interaction 
between the enzyme and substrate (Krishnaswamy, 2004). While trypsin is theoretically 
capable of cleaving after any accessible lysine and arginine residues in a protein (Roach 
et al., 1997), the substrate specificity of the coagulation proteases is much more 
restricted, and the number of cleavages per substrate molecule is typically limited.  In 
contrast to trypsin, coagulation protease specificity for substrates stems from binding 
interactions at sites remote from the catalytic active site called exosites. 
 
Coagulation Protease Exosites and Auxiliary Domains 
 Reversible active site inhibitors of coagulation proteases inhibit cleavage of small 
peptidyl substrates by a classic competitive inhibition (Figure I-4A). This is because the 
substrate  is  recognized solely  by  structures surrounding the enzyme active site, and the 
inhibitor and substrate bind in a mutually exclusive way to the catalytic domain active 
site. The same inhibitor causes mixed hyperbolic inhibition (Figure I-4B) of cleavage of 
the  normal  plasma  macromolecular  substrates  of  the protease,  indicating  the  binding 
 
Figure I-4. Models for enzyme inhibition The models illustrate conversion of a substrate (S) to 
product (P) by an enzyme (E), in the presence or absence of a reversible active site inhibitor (I). 
(A) A model for pure competitive inhibition. (B) A model for mixed hyperbolic inhibition. Steps 
that are largely responsible for determining Km, kcat, and Ki are indicated.  and  represent 
factors that depends on the nature of the inhibitor. 
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energy that drives the physiologic enzyme-substrate interaction occurs outside of the 
areas where the inhibitor binds (i.e. remote from the active site). These extended 
macromolecular recognition sites are called exosites, and can be located in the catalytic 
domain, as in the case of -thrombin (Davie and Kulman, 2006), or in the N-terminal 
auxiliary domains, as has been demonstrated for factors VIIa, IXa, Xa, and XIa (Baugh et 
al., 2000; Krishnaswamy, 2004; Bock et al., 2007; Ogawa et al., 2005). For example, 
during activation of factor IX by factor XIa, factor IX initially binds to one of the 
auxiliary domains on factor XIa (Ogawa et al., 2005). This exosite interaction presents 
the cleavage site on factor IX to the factor XIa active site on the catalytic domain for 
catalysis. The importance of exosite interactions during factor IX activation by factor XIa 
will be addressed in Chapters V and VI. 
 In addition to containing exosites, coagulation protease auxiliary domains (Figure 
I-2) serve to localize the enzyme, and thus the clotting process, to areas of vascular 
injury. A critical auxiliary domain for the coagulation protease zymogens prothrombin 
and factors VII, IX and X is the N-terminal -carboxyglutamic acid (Gla) domain (Furie 
and Furie, 2009). The Gla domain of factor IX is shown in Figure I-5.  Gla domains are 
rich  in glutamic acid  residues that have been modified by addition of a carboxyl group 
to the -carbon in a process that depends on reduced vitamin K. The -carboxyglutamic 
acid residues in the Gla domains coordinate the binding of calcium and magnesium ions, 
which  are  critical  for  proper  folding  of the domain and protein  function. The divalent 
cations in the Gla domain interact with negatively charged phospholipids in platelet  and 
cell membranes, with the non-polar side chains of N-terminal residues of the domain 
inserting into the lipid bilayer.  -carboxyglutamic acid is widely distributed in the animal 
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Figure I-5. The Gla domain of factor 
IX. Shown is a ribbon diagram of the Gla 
domain from human factor IX, extending 
from the N-terminal tyrosine residue one 
to the C-terminal valine residue 46. The 
peptide backbone is indicated by the red 
ribbon. Side chains of -carboxyglutamic 
acid residues (), and Lys5, Leu6, and 
Phe9 in the omega loop, are in green. 
Nitrogen and oxygen atoms on these 
residues are indicated in blue and red, 
respectively. Calcium ions are shown as 
light blue spheres. The three -helices of 
the Gla domain are indicates as A, B and 
C in gray lettering.  The omega loop is 
involved in binding to phospholipid 
membranes.  
 
Image courtesy of Dr. S. Paul Bajaj 
(University of California, Los Angeles)  
 
 
kingdom, having been found in a variety of organisms such as the sea squirt (Ciona 
intestinalis), fruit flies (Drosophila melanogaster), and marine snails (Conus textile), 
which do not possess a vertebrate-type coagulation mechanism (Bandyopadhyay, 2008).  
 Activation of vitamin K-dependent coagulation factors (prothrombin and factors 
VII, IX and X), for the most part, is characterized by reversible assembly of the activating 
protease and substrate on a phospholipid surface (Krishnaswamy, 2004). In these 
reactions, the Gla domain is critical for binding to the phospholipid membrane, and in 
some cases with other proteins (cofactors and substrate), that are instrumental in proper 
positioning of substrate and protease relative to each other for efficient catalysis (Waters 
et al., 2006). An exception to this rule is activation of factor IX by factor XIa, which is 
not affected by phospholipids (Mannhalter et al., 1984; Gailani and Broze, 2001). This is 
likely due to the fact that factor XIa lacks a Gla domain and does not bind to 
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phospholipid membranes. Factor IX does bind phospholipid through its Gla domain, so it 
is likely that factor XIa interacts with factor IX at a site distinct from the phospholipid 
binding region. The four auxiliary domains that comprise the N-terminal non-catalytic 
portion of factor XIa (Figure I-2), are distinctly different from the auxiliary domains of 
vitamin K-dependent proteases.  In Chapters V and VI we will show that a protein-
protein interaction between auxiliary domains on factor XIa and the factor IX Gla domain 
is required for normal activation of factor IX by factor XIa. 
 
Factor XI During Vertebrate Evolution  
 The specific genetic events in which the genes of trypsin-like enzymes were 
attached to genes for various auxiliary domains to form the coagulation proteases have 
not been identified; however, evidence from comparative genomics clearly indicates that 
gene duplication and exon shuffling were involved in placing a diverse array of domains 
at the N-termini of the genes for these proteases (Jiang and Doolittle, 2003). This process 
is undoubtedly responsible for the differentiation (specificity) of the enzymes involved in 
fibrin clot formation. Because blood clotting follows the same basic pattern in all 
vertebrates, following the development of clotting enzymes through vertebrate evolution 
allows the identification of an initial and essential set of clotting enzymes for fibrin 
formation. A comparison of the genomes of the puffer fish (fugu rubripes) and the 
invertebrate Ciona intestinalis (the sea squirt) reveal that a functioning coagulation 
mechanism emerged in the time interval following the last common ancestor of these 
diverging chordates, a period of less than 100 million years (Jiang and Doolittle, 2003).   
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 Analysis of the genomes of the puffer fish, and more recently the zebra fish 
(Danio rerio) show that jawed fish possess homologs for the coagulation factors shown 
in Figure I-6. Note that while these species have all of the vitamin K-dependent 
proteases found in mammals, they lack genes for factor XI and its homolog PK, and for 
factor XII (Ponczek et al., 2008). In factor XI and PK, the trypsin-like protease is linked 
to  four  auxiliary  domains   called  apple  domains   (discussed  in  Chapter  III).   Apple 
 
Figure I-6. Schematic diagram of the predicted 
protease reactions involved in fibrin formation 
in fish.  Jawed fish (teleosts) have orthologs for 
all of the vitamin K-dependent coagulation 
proteases found in mammals (prothrombin and 
factors VII, IX and X); the cofactors tissue factor 
(TF), factor V and factor VIII, and the regulatory 
protease inhibitor tissue factor pathway inhibitor 
(TFPI).  Teleosts do not have orthologs for factor 
XI, prekallikrein or factor XII.  However, they do 
have genes for the likely ancestors of these 
proteases: hepatoctye growth factor or 
plasminogen in the cases of factor XI and 
prekallikrein; and hepatoctye growth factor 
activator in the case of factor XII.  The immediate 
predecessor of factor XI and prekallikrein first 
appears in amphibians, as does factor XII. 
 
 
domains are members of the PAN (Plasminogen/Apple/Nematode) domain family, which 
are related to the N-terminal regions of plasminogen and hepatocyte growth factor 
(Tordai, 1999). It is likely that the apple domains of factor XI and PK are derived from a 
protease such as plasminogen or hepatocyte growth factor, both of which are found in 
fish (Ponczek et al., 2008).  While fish have no homologs for factor XI or PK, a gene for 
a trypsin-like protease with four apple domains that is clearly the direct ancestor for these 
proteins first appears in amphibians (frogs - Xenopus). A duplication event involving this 
ancestral gene occurred during mammalian evolution after the divergence of monotremes 
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(egg-laying mammals such as the platypus) from marsupial and placental mammals, 
giving rise to factor XI and PK.  Similarly, the gene for factor XII first appears in 
amphibians, as a result of a duplication of the gene for its homolog, hepatocyte growth 
factor activator. The appearance of factor XII and the predecessor of factor XI/PK in 
amphibians may indicate that factor XIIa is an activator of the latter, just as it is an 
activator of factor XI and PK in mammals.  
 Thus, it is apparent that factor IX appeared much earlier in vertebrate evolution 
than factor XI, clearly indicating that a mechanism for factor IX activation must have 
existed that is not depicted in the classic cascade model in Figure I-1A. This 
inconsistency in the old model is not an issue in current models of coagulation (Figure I-
1B - Discussed in detail below), where factor IX can be activated by both factor VIIa and 
factor XIa. The selective advantage gained by having factor XIa as a second activator of 
factor IX is unknown, but it is clear that significant changes have occurred in factor XI 
since its divergence from the factor XI/PK precursor that facilitate factor IX activation.  
This issue will be covered in detail in chapters V and VI. 
 
Models of Fibrin Clot Formation 
 Fibrin clot formation was originally envisioned as a cascade or waterfall-like 
sequence of proteolytic reactions, with one coagulation protease activating the next 
zymogen, in a linear sequence (Figure I-1A) (Macfarlane, 1964; Davie and Ratnoff, 
1964).  In this model, coagulation can be triggered by two distinct mechanisms. One 
mechanism involves activation of factor XII in a process called contact activation 
(Figure I-7), which requires the protease zymogen PK and the cofactor HMWK. Contact  
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Figure I-7. Plasma contact activation. Contact activation is initiated by the slow activation of 
factor XII (FXII) to -factor XIIa (FXIIa), probably by autoactivation, when plasma is exposed 
to a negatively charged surface (reaction 1). Reciprocal activation of prekallikrein (PK) to -
kallikrein (-kal) by FXIIa (reaction 2), and FXII by -kal (reaction 3) enhances FXII 
activation. FXIIa promotes coagulation through conversion of factor XI (FXI) to factor XIa 
(FXIa) (reaction 4). -kal also cleaves high molecular weight kininogen (HK) to liberate 
bradykinin (reaction 5). Note that HK is required for PK and FXI binding to the contact surface. 
 
activation is triggered in vitro by exposure of blood to various surfaces, usually with a 
negative charge, such as silica or glass (Gailani and Broze, 2001). Possible physiologic 
activators of contact activation are discussed below. The second initiation mechanism 
involves the binding of factor VIIa in plasma to its cofactor, tissue factor (TF) (Figure I-
1A). Note that in the classical model, factor IX is activated only by factor XIa. As 
discussed in the previous section, this seems unlikely given the relatively recent addition 
of factor XI to vertebrate coagulation. 
 Modern coagulation models incorporate a junction that allows for factor IX to be 
activated by more than one enzyme (Figure I-1B), and the resulting mechanism overall is 
not as much a cascade as a group of proteolytic reactions that may play roles in both 
initiating and consolidating coagulation (Broze et al., 1990; Davie et al., 1991). Factor IX 
activation, therefore, lies at a critical junction in the coagulation process because its 
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activation is accomplished by two distinct reaction pathways, each of which may be 
triggered by different stimuli related to vascular damage.  
 
Tissue Factor and Initiation of Blood Coagulation 
 In current models of fibrin formation (Figure I-1B), coagulation at a site of 
vascular damage is initiated by formation of a complex between plasma factor VIIa and 
the non-enzymatic integral membrane protein TF, which is exposed to blood at a site of 
injury. TF is a 47,000 Dalton trans-membrane glycoprotein member of the cytokine 
receptor family that is constitutively expressed on many cells that underlie vascular 
endothelium, such as fibroblasts, pericytes, astrocytes, and cardiomyocytes (Mackman et 
al., 2007) (Figure I-8A). TF expression can also be induced in platelets and monocytes, 
establishing an additional source for this cofactor at injury sites. Factors VII and VIIa are 
the  natural  ligands of TF. Factor VII must bind to TF in order to be efficiently activated, 
 
Figure I-8. Tissue factor (TF). (A) Photomicrograph of a human arteriole. 
Immunohistochemistry was performed with a polyclonal antibody to human TF. Cells 
expressing TF appear red.  Hematoxylin was used as a counterstain. (B and C)  Space-filling 
models of human factor VIIa in complex with the extra-cellular portion of TF (green). The 
factor VIIa catalytic domain is blue and the non-catalytic light chain is in purple.  Calcium ions 
in the factor VIIa Gla domain appear as yellow spheres. Model courtesy of Dr. S. Paul Bajaj. 
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and factor VIIa requires TF to efficiently activate its substrates, factors X and IX. While 
the majority of coagulation factors circulate as inactive zymogens that require proteolytic 
activation, approximately 1% of circulating factor VII is in the form of factor VIIa. 
Factor VIIa and factor VII bind to TF, when TF is exposed to flowing blood (Figure I-
8B and 8C). Factor VIIa/TF is able to auto-activate FVII that is in complex with TF. This 
feedback process amplifies the local concentration of factor VIIa/TF.  
 Factor VIIa/TF converts some factor X and factor IX to the active proteases factor 
Xa and factor IX to factor IXa, respectively (Broze et al, 1990; Davie et al., 1991; 
Mackman, 2007). The relatively small amount of factor Xa generated initially converts 
some prothrombin to -thrombin (Figure I-1B), which cleaves fibrinogen into insoluble 
fibrin, and activates the cofactors, factor V and factor VIII. Just as TF serves as a cofactor 
that enhances the efficiency of factor VIIa, factors Va and VIIIa enhance the catalytic 
efficiencies of factor Xa and factor IXa, respectively, resulting in greater than 100,000-
fold enhancement of prothrombin activation by the system (Furie and Furie, 2009). 
However, the activity of factor VIIa/TF at a wound site may be transient, as the complex 
is a target for inhibition by the Kunitz-type proteinase inhibitor, tissue factor pathway 
inhibitor (TFPI - Figure I-1B). Furthermore, the TF exposed by vascular damage is 
quickly covered by the growing clot. This has lead to speculation that factor VIIa/TF is 
critical for the initiation of clot formation, but may not be sufficient to sustain factor X 
activation over time to consolidate the process in all circumstances. In many instances, 
sustained factor X activation would require factor IXa and factor VIIIa.  This hypothesis 
is consistent with the severe bleeding seen in patients lacking factors IX or VIII, 
condition known as hemophilia B and A, respectively (Ragni et al., 2009). 
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The Intrinsic Pathway of Blood Coagulation 
 As shown in Figure I-1B, the factor VIIa/TF complex activates both factor X and 
factor IX, but it has long been recognized that factor IX can be activated by a factor 
VIIa/TF-independent process. Indeed, factor IX activation by factor XIa was reported 
nearly 20 years before it was appreciated that factor IX was activated by factor VIIa/TF. 
Factor XIa is an enzyme of the traditional intrinsic pathway for initiating coagulation 
(represented by the white arrow in Figure I-1A), which also contains the proteases factor 
IX, factor XII, and PK, and the cofactor HMWK. Activation of coagulation through the 
intrinsic pathway requires a charged surface (Figure I-7). While the events involved in 
initiating coagulation through factor VIIa/TF (the classical extrinsic coagulation 
pathway) are reasonably well understood, the identity of the physiologic counterparts for 
the surface or cofactor that initiates coagulation through the intrinsic cascade is a matter 
of debate. Some studies suggest that collagen exposed by vascular damage can facilitate 
factor XII activation (Renné et al., 2005), while others have identified RNA from 
damaged cells (Kannemeier et al., 2007) and polyphosphates from platelet -granules 
(Smith et al., 2006) as inducers of contact activation. On a surface, factor XII is slowly 
converted to factor XIIa, which then converts PK to -kallikrein, which reciprocally 
activates additional factor XII (Figure I-7). Factor XIIa also converts factor XI to factor 
XIa, which converts factor IX to factor IXa. There is no reported functional difference 
between factor IXa that has been produced by factor XIa or by factor VIIa/TF.   
 The sequence of reactions and molecular interactions in the intrinsic pathway 
have been studied for many years, but the physiologic significance of the pathway as a 
whole, as depicted in Figure I-1A, is not established and is a topic of debate (Renné et 
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al., 2005; Pedicord et al., 2007; Blat and Seiffert 2008) It has been widely accepted that 
factor XIIa activation of the intrinsic cascade is not important for normal coagulation 
(hemostasis) in vivo because persons with factor XII deficiency do not have a bleeding 
disorder (Gailani and Broze, 2001). Factor XI deficiency does result in abnormal 
bleeding that varies among individuals, typically causing a problem after trauma or 
surgery (Seligsohn, 2007). The phenotypic difference in the deficiency states of these two 
proteins suggests that enzymes other than factor XIIa mediate factor XI activation during 
hemostasis. For example, thrombin is capable of activating factor XI (Naito and 
Fujikawa, 1991; Gailani and Broze, 1991), and evidence from ex-vivo human plasma 
systems suggest that under some circumstances prothrombin activation is dependent on 
factor XI in the absence of factor XII (von dem Borne et al., 1995; Kravtsov et al., 2009).  
 It is now thought that factor XI is not part of a mechanism for initiating fibrin clot 
formation (at least under normal circumstances), but instead is activated late in the 
process (possibly by thrombin or factor XIIa), and contributes to hemostasis by 
sustaining factor IX activation to supplement factor IXa produced by the factor VIIa/TF 
complex. Bleeding in hemophilia B is much more severe than in factor XI deficiency 
(Seligsohn, 2007), indicating factor IX activation by factor VIIa/TF is likely to be at least 
as important as activation by factor XIa. Thus, the model in Figure I-1B not only 
explains bleeding disorders associated with various factor deficiencies better than the 
model in Figure I-1A, but is also consistent with genomic analyses showing that factor 
IX was present in vertebrates before factor XI. The role of factor XIIa in the activation of 
factor XI during normal coagulation remains a subject of controversy. Experiments in 
Chapter IV will examine factor XI activation by factor XIIa and -thrombin. 
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Summary 
 Formation of a fibrin clot is mediated by a tightly regulated series of proteolytic 
reactions involving trypsin-like plasma proteases and their cofactors. Factor IX, which 
lies at a critical junction in the coagulation process, is activated by two distinct 
mechanisms mediated by factor VIIa and factor XIa. There has been a recent increase in 
interest in the biology of factor XIa and factor XIa activation of factor IX, as studies in 
animal models (Gailani and Renné, 2007a, 2007b) and human epidemiologic data 
(Meijers et al., 2000; Doggen et al., 2006) suggest that this mechanism may make a 
significant contribution to pathologic coagulation disorders such as vascular thrombosis 
(Wang et al., 2006; Tucker et al., 2009), reperfusion injury in stroke (Kleinschnitz et al., 
2006), and disseminated intravascular coagulation (Tucker et al., 2008). A major goal of 
the work in this thesis is to investigate the mechanisms by which factor XIa, a protease 
with a distinctly different structure than other coagulation proteases, activates factor IX.  
We postulate that the mechanism by which factor IX is activated by factor XIa is 
markedly different than the mechanism for factor IX activation by factor VIIa/TF, as 
factor XIa requires neither phospholipid or a cofactor to mediate the process. We have 
also pursued interesting preliminary data on the mechanism by which zymogen factor XI 
is converted into an active protease. This work  identified a novel form of activated factor 
XIa that may represent the major physiologic species of this protease. 
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CHAPTER II 
 
 
FACTOR IX STRUCTURE AND ACTIVATION 
 
 
Introduction 
 
 This chapter will cover the structure of factor IX, with a particular emphasis on 
how the structure relates to factor IX activation.  The importance of factor IX in 
hemostasis is demonstrated by the severity of the bleeding in the disorder hemophilia. 
Hemophilia B, congenital deficiency of factor IX, is an X-linked disorder that occurs in 1 
in 30,000 male births (Ragni et al., 2009). People with severe hemophilia B suffer from 
spontaneous hemorrhage into soft tissues and joints that can be crippling or life 
threatening. Factor IX arose from a gene duplication that also produced factor X, with 
which it shares a similar structure. As discussed in Chapter I, factor IX is classified as an 
intrinsic pathway protein in the traditional cascade model of coagulation (Figure I-1A), 
and forms a link between contact activation and thrombin generation. Because the 
duplication of the primitive gene that resulted in formation of the factor IX gene 
substantially predates the appearance of factor XI in vertebrates (Ponczek et. al., 2008), 
factor IX must be activated by other mechanisms as well. In current models of 
coagulation (Figure I-1B), the major mechanism for factor IX activation is through the 
factor VIIa/tissue factor complex, and the most likely contribution of activated factor IX 
to hemostasis is as a separate activator for factor X that is not inhibited by TFPI. In this 
scheme, factor IX activation through factor XIa serves to supplement factor IX activation 
by factor VIIa/TF.  
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 Human factor IX is a 57,000 Dalton single chain glycoprotein composed of 415 
amino acids, with approximately 17% carbohydrate (DiScipio et al., 1978). It is 
synthesized in hepatocytes, and circulates in plasma at a concentration of ~90 nM 
(Schmidt and Bajaj, 2003).  Factor IX is structurally similar to factors VII and X (Figure 
I-2), and the coagulation regulatory protease protein C (Furie and Furie, 2009). Starting 
from the N-terminus, factor IX is composed of an N-terminal Gla domain, a hydrophobic 
stack region, two epidermal growth factor (EGF) domains (EGF1 and EGF2) connected 
by  a  short linker,  an activation peptide region that is removed completely upon protease  
 
 
Figure II-1. Primary amino acid sequence and disulfide bond structure of human factor 
IX. -gluamyl-carboxyglutamic acid residues in the Gla domain are shown in green circles, 
and amino acids of the activation peptide are shown in blue.  Cleavage after Arg145 and 
Arg180 are required to convert zymogen factor IX to the active protease factor IXa.  The 
residues of the protease domain catalytic triad are shown in red circles.  The non-catalytic 
portion of factor IXa contains the Gla domain and the two epidermal growth factor domains 
(EGF1 and EGF2). Cysteine residues are in yellow circles. Not shown are the N-terminal 
signal peptide and pre-pro-leader sequence that binds to -glutamyl-carboxylase. 
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activation, and a C-terminal trypsin-like catalytic serine protease  domain (Figure II-1). 
In Figure II-2, a schematic diagram of factor IX is shown along with a space-filling 
model based on structures of other vitamin-K dependent proteases (there are no published 
crystal structures for factor IX).  Note that the Gla domain and catalytic domains are at 
the extreme ends of the molecule. When factor IX binds to a phospholipid surface, this 
elongated arrangement facilitates placement of the catalytic domain at the correct 
distance above the membrane for optimal activation by factor VIIa (Waters et al., 2006). 
 
Figure II-2. Domains of factor IX. Shown at the top is a schematic diagram of  factor IX 
with the domains labeled. Abbreviations are: Gla - -carboxyglutamic acid domain, EGF - 
epidermal growth factor domain, CAT - catalytic domain. The activation peptide is shown in 
green.  At the bottom of the figure is a composite space filling model of human factor IX 
cleaved after Arg145 (factor IX) with the non-catalytic domains indicated by the purple 
arrows.  The catalytic domain is in red.   Calcium ions in the Gla domain are represented by 
yellow spheres.  Model courtesy of Dr. S. Paul Bajaj. 
 
 Factor IX is converted to the active protease factor IXa by proteolytic cleavage 
after Arg145 and Arg180, releasing the internal activation peptide. The resulting 
polypeptides that comprise factor IXa, referred to as the light chain (Gla domain, and 
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the EGF1 and EGF2 domains) and the heavy chain (catalytic domain), are held together 
by a disulfide bond between Cys132 and Cys289. The Gla, aromatic stack, EGF1, EGF2, 
and catalytic domains of factor IX are all involved in protein-protein interactions with 
substrates, phospholipid surfaces and cofactors. In addition, the Gla domain appears to be 
of primary importance in interacting with factor XIa in solution (Aktimur et al., 2003).  
 
Gla Domains  
 As briefly discussed in Chapter I, Gla domains are membrane binding motifs that 
support interactions with phospholipid membranes containing phosphatidylserine, such as 
those typically found on activated platelets, cells undergoing apoptosis, and damaged 
cells  at a site of vascular injury.  The factor IX Gla domain  (residues 1-40 - Figure II-3) 
is post-translationally -carboxylated on its 12 glutamic acid residues in a reaction 
catalyzed by the vitamin K-dependent enzyme  glutamyl-carboxylase (Suttie, 1985; Wu, 
 
Figure II-3. The factor IX 
Gla domain. The top image 
shows the factor IX Gla 
domain structure, from a 
crystal structure of amino 
acids 1-46 in complex with a 
binding protein from the 
venom of the snake 
Trimeresurus flavoviridis. -
carboxyglutamic acids are in 
red and residues that insert 
into phospholipid membranes 
are in yellow.  The yellow 
line indicates the membrane 
surface. The red arc indicates 
residues 40-46, which were 
implicated in initial studies  
as  a  factor XIa  binding  site.  
The image is adapted from Shikamoto et al. (J. Biol. Chem. 278;24090-24094, 2003). At the 
bottom of the figure is a comparison of Gla domain sequences for bovine (b IX) and human (h 
IX) factor IX, and human factor VII (h VII).  Amino acids involved in binding calcium or 
magnesium ions are indicated at the top.  Residues in factor IX replaced by factor VII sequence in 
the recombinant chimeras discussed in the text are indicated at the bottom.  
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1991). Once modified, these glutamic acid residues coordinate binding of calcium and 
magnesium ions, resulting in proper structural rearrangement of the entire Gla domain. 
The properly folded factor IX Gla domain binds negatively charged phospholipids, such 
as phosphatidylserine, by calcium and/or magnesium bridging with the negatively 
charged phospholipid head groups (Swairjo et al., 1995; Nelsestuen and Ostrowski, 1999; 
Huang et al., 2003), as well as by hydrophobic interactions involving residues Lys5, Leu6 
and Phe9 as shown in Figure II-3 (Huang et al., 2003).  
 The factor IX Gla domain is essential for normal binding of factor IX to factor 
XIa, as factor IX with the homologous Gla domain from factor VII (factor IX/VII-Gla) 
does not bind to factor XIa (Aktimur et al., 2003). Factor IX/VII-Gla is activated poorly 
by factor XIa, but is activated normally  by factor VIIa/TF. Similarly, recombinant factor 
IX expressed in media containing warfarin, which inhibits vitamin K-dependent -
carboxylation, is activated poorly by factor XIa (Aktimur et al., 2003). Replacement of 
the factor IX Gla domain with the Gla domain from protein C also resulted in a factor IX 
molecule that could be activated normally by factor VIIa/TF, but not by factor XIa 
(Ndonwi et al., 2007). Because the N-terminal portion of the Gla domain, known as the 
-loop, is involved in lipid interactions, and lipid does not affect factor XIa catalyzed 
factor IX activation (Mannhalter et al., 1984; Gailani and Broze, 2001), it is reasonable to 
conclude that the area of the Gla domain that interacts with factor XIa lies in the C-
terminus of the Gla domain. These findings suggest different epitopes within the factor 
IX Gla domain bind factor XIa and the factor VIIa/TF complex, and may explain 
structural differences between the Gla domain of factor IX and those of other vitamin K 
dependent proteins, which are not activated by factor XIa.  
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 The coordinated binding of Ca2+ ions is required for proper -loop conformation 
and membrane binding during factor IX activation by the factor VIIa/TF complex, and 
for activation of factor X by factor IXa (Huang et al., 2003). The factor IX Gla domain 
is thought to interact with an area of tissue factor near the phospholipid surface when 
engaged with the factor VIIa/TF complex. The modeled structure of the factor IX Gla 
domain proposed by Chen et al. (Chen et al., 2002) predicts that residues 18 and 19, 
which are located in a turn between the first and second -helices (helices A and B), are 
involved in an interaction with Arg36 on factor VIIa. Recombinant chimeras in which -
helices from the factor IX Gla domain have been exchanged for the equivalent helices 
from factor VII are activated normally by the factor VIIa/TF complex (Sun and Gailani, 
unpublished data). However, factor IX activation by factor XIa is abnormal for the 
chimera with replacement of the C-terminal helix C (Chimera 4 - Figure II-3), 
suggesting a unique interaction between this area and factor XIa. In experiments 
described in Chapters V and VI, activation of factor IX by factor VIIa/TF will be 
compared to activation by factor XIa. 
 
Epidermal Growth Factor (EGF) Domains 
 The factor IX EGF1 domain (residues 47-83) is connected to the Gla domain by a 
short aromatic amino acid stack region that likely contributes to the curvature of the 
molecule and relative positions of the EGF1 and Gla domains (Chen et al., 2002). 
Multiple lines of evidence from mutational and biochemical analyses (Ndonwi et al, 
2005), and molecular modeling studies (Chen et al., 2002) suggest a role for the factor IX 
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EGF1 domain in interactions with TF, but not with factor XIa (Zhong et al, 1994; 
Ndonwi et al., 2007).  
 The factor IX EGF2 domain (residues 88-127) is implicated in binding factor 
VIIIa, and in interactions with platelets in the "tenase" complex involved in the activation 
of factor X (Wilkinson et al., 2002). Experiments with EGF2 chimeras suggest this 
domain plays a role in assembling the factor X activating complex, and a minor role in 
platelet binding (Wilkinson 2002). In factor IX, EGF2 makes extensive contacts with the 
catalytic domain (Hopfner et al., 1999; Fribourg et al., 2006), and is also required for 
normal binding to the A2 subunit of factor VIIIa (Celie et al., 2002). There is no evidence 
that the EGF2 domain of factor IX interacts with factor XIa. 
  
Activation Peptide 
 The Gla and EGF domains, which make up the factor IX light chain, are 
connected to the catalytic domain (heavy chain) by a 35 amino acid (11,000 Dalton) 
activation peptide (DiScipio 1978). Removal of the activation peptide to generate factor 
IXa requires two proteolytic cleavages, and the activation peptide has no known 
function once removed from factor IX.  In the space-filling model in Figure II-2 factor 
IX has been cleaved at the N-terminus of the activation peptide (Arg145-Ala146 bond) 
where it attaches to EGF2. Cleavage at the C-terminal end of the activation peptide 
(Arg180-Val181 bond) allows Val181 to (Val16 in chymotrypsinogen numbering) form a 
salt bridge with Asp364 of the catalytic domain (Asp194 in chymotrypsinogen numbering) 
that allows the protease catalytic site to assume an active conformation. Although 
cleavage of the C-terminus of the activation peptide without cleavage at the N-terminus is 
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sufficient to generate an active protease (referred to as factor IXa), the protease is a 
poor activator of factor X (Griffith et al., 1985). Interestingly, activation of factor IX by 
factor VIIa/TF appears to always proceed by cleavage at the N-terminal Arg145-Ala146 
bond first (Figure II-4A), producing an non-active intermediate called factor IX. Thus, 
complete removal of the activation peptide is required for normal activation of factor IX 
by factor VIIa/TF. Determining the order of bond cleavage of factor IX by factor XIa is a 
major goal of this thesis project.  
 
Figure II-4. Factor IX activation. (A) Factor IX is converted to factor IXa by cleavage of 
the Arg145-Ala146 and Arg180-Val181 bonds, releasing the activation peptide (green ribbon).  
Conversion of inactive catalytic domain (red circle) to active protease (green three-quarter 
circle) requires cleavage at Arg180-Val181. (B) During activation by factor VIIa/TF, factor 
IX is cleaved at Arg145-Ala146 forming factor IX. Factor IX cleavage at Arg180-Val181 is 
a minor reaction. (C) When factor XIa activates factor IX, intermediate is not observed. 
Abbreviations: FIX - zymogen factor IX; FIX - the large fragment of factor IX containing 
the activation peptide and protease domain; CD - catalytic domain, the active protease 
domain of factor IXa; and LC - light chain, the Gla domain and EGF domains of factor IX 
and factor IXa. Bonds cleaved in each step are indicated in blue. 
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Activation of Factor IX 
 As discussed above, factor IX must be cleaved after Arg145 and Arg180 for full 
conversion to the protease factor IXa. The predicted structure of factor IX (Figure II-2) 
does not give an indication of which peptide bond is likely to be cleaved first, as both 
cleavage sites appear to be accessible at either end of the solvent exposed activation 
peptide. Reducing western blots of time courses of factor IX activation by the factor 
VIIa/TF complex typically reveal the accumulation of the activation intermediate factor 
IX, cleaved only after Arg145 (Figure II-4B). Similar time courses in which factor XIa 
was the activating enzyme revealed only slight accumulation of the same intermediate at 
most, with most experiments showing no accumulation at all (Figure II-4C). Although 
there is no obvious reason for this difference, the structures and evolutionary lineages of 
factor VIIa and factor XIa are consistent with different mechanisms for factor IX 
activation by these proteases.  
 Exosite interactions align the enzyme and substrate for efficient cleavage, and 
must account for the geometry of the substrate molecule, as well as changes in 
conformation that accompany conversion of the zymogen to an activation intermediate. 
Although both cleavages in factor IX are made by factor VIIa and factor XIa, these 
enzymes appear to process the individual cleavages differently. It is clear that these 
proteases have different structures. Factor VIIa, which is structurally similar to factor IX, 
has the typical elongated profile of a vitamin K-dependent coagulation protease, as 
shown in the space-filling model in Figure II-5.  The structure of factor XIa, which is 
considered in the next chapter, is substantially different, consistent with the structure-
function studies discussed above that indicate factor VIIa and factor XIa bind to distinctly  
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Figure II-5. Factor IX undergoing activation by factor VIIa/TF. Shown are two space-
filling models of human factor IX (catalytic domain in red, non-catalytic domains in white) 
in complex with factor VIIa (catalytic domain in blue, non-catalytic domains in purple) and 
the extracellular portion of tissue factor (green). Calcium ions in the factor VIIa and factor 
IX Gla domains appear as yellow spheres.  In this image, factor IX has already been cleaved 
at the Arg145-Ala146 bond to form the intermediate factor IX. Images courtesy of S. Paul 
Bajaj, University of California Los Angeles. 
 
different domains on factor IX. Furthermore, while factor VIIa/TF activates both factor 
IX and factor X, factor XIa activates only factor IX. A difference in binding recognition 
sites for the two proteases is, therefore, expected. If exosite interactions between factor 
IX and factor VIIa or factor XIa involve the auxiliary domains of these proteases, then 
presentation of the factor IX scissile bonds to either catalytic domain may be distinctly 
different. In addition, the manner in which the two proteases interact with a singly 
cleaved factor IX activation intermediate may also be different.  
 Factor IX activation by factor XIa is potentially a more complex process than is 
activation by factor VIIa/TF. Factor XIa appears to generate no intermediate when 
cleaving factor IX. This could be interpreted as indicating that both cleavages required 
for factor IX activation are made without formation or release of an intermediate.  As 
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mentioned in Chapter I, and covered in detail in Chapter III, factor XIa is a homodimer, 
and it has been suggested that the two catalytic domains of factor XIa may cleave both 
scissile bonds of factor IX simultaneously or in rapid succession without release of an 
intermediate (Wolberg et al., 1997; Samuel et al., 2007).  Alternatively, factor XIa could 
cleave the scissile bonds of factor IX sequentially, with the second cleavage being as fast 
or faster than the initial cleavage. While this latter mechanism could require both factor 
XIa catalytic domains, it is also possible that each subunit of the factor XIa dimer can 
activate factor IX independently of the other subunit. In this case one factor XIa dimer 
may bind two factor IX molecules simultaneously. These issues are addressed in detail in 
the experiments described in Chapter V. 
 
Summary 
 It seems clear that factor IX is activated by the factor VIIa/TF complex in a 
process that involves (1) binding of factor IX to the complex, (2) cleavage of the Arg145-
Ala146 bond to form the intermediate factor IX, (3) release of the intermediate followed 
by rebinding to the complex, and (4) cleavage of the Arg180-Val181 bond to form the 
final product, factor IXa. Factor IX activation by factor XIa, on the other hand, may 
involve a distinctly different process.  As no intermediate appears to form during factor 
IX activation by factor XIa, we do not gain significant information on the mechanism 
involved by studying western blots of time courses such as the one shown in Figure 
Figure II-4C. The main goals of the work described in this thesis are to determine (1) the 
order of bond cleavage of factor IX by factor XIa, (2) whether factor XIa requires both 
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catalytic domains to properly process factor IX, and (3) the importance of exosite 
interactions as they relate to the mechanism of activation of factor IX by factor XIa. 
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CHAPTER III 
 
 
FACTOR XI STRUCTURE 
 
 
Introduction 
 
 Human coagulation factor XI is a 160,000 Dalton homodimer (Figure III-1A) 
composed of two identical 80,000 Dalton subunits (Figure III-1B) that are joined by a 
single disulfide bond. Each subunit is composed of an N-terminal series of four apple 
domains, numbered A1 through A4, followed by a C-terminal trypsin like serine protease 
domain (Figure III-2) (Fujikawa et al., 1986; McMullen et al., 1991A; Papagrigoriou et 
al., 2006). Factor XI is synthesized in hepatocytes and circulates in plasma at a 
concentration of ~30 nM in a complex with the glycoprotein HMWK. Each subunit of 
factor XI is activated through cleavage by factor XIIa or thrombin. Factor XI is the only 
coagulation factor, and only plasma serine protease, that is known to be a dimer. The only 
other homodimeric serine protease that has been reported is granzyme A, which is 
secreted by cytotoxic T lymphocytes (Bell et al., 2003). Although factor XI and 
granzyme A both have an S1A trypsin-like serine protease domain, they are not related 
enzymes. While factor XI has a catalytic domain that is similar to those of other 
coagulation proteases, it shares the highest homology with the monomeric protease PK 
(Discussed in Chapter I). The catalytic domains of factor XI and PK are 68% 
homologous (Fujikawa et al., 1986; Chung et al., 1986), consistent with the fact that the 
duplication that gave rise to these paralogs was recent in comparison to the appearance of 
other coagulation proteases. Overall, factor XI and PK are 58% identical at the amino 
acid level.  
   
Figure III-1. Structure of human factor XI. (A) Dimer and (B) Monomer. In both images the apple 1 (A1) domains are gray, A2 blue, A3 
orange, and A4 yellow. The protease domains are dark red.  Note the interchain disulfide bond formed by residue  Cys321 in the A4 domains from 
each subunit at the top of panel A.  Images courtesy of Jonas Emsley, University of Nottingham (Papagrigoriou et al., 2006). (C) Amino acid 
sequence and disulfide bond structure of human factor XI monomer.  The apple domains are designated A1-A4. Cys321 in A4 forms the 
disulfide bond between the dimer subunits. Factor XI is cleaved after Arg369 to form factor XIa. A disulfide bond between Cys362 and Cys482 
connects the catalytic domain and heavy chain in factor XIa. His413, Asp462 and Ser557 (His57, Asp102, Ser195 in chymotrypsin) form the 
protease catalytic triad, and are shown in red. Diagram modified from McMullen et al., 1991A.  
 
A 
B 
C 
3
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Activation of Factor XI 
 Conversion of a factor XI subunit to factor XIa involves cleavage of the Arg369-
Ile370 bond.  Cleavage results in a heavy chain (the four apple domains) and catalytic 
domain (light chain) that remain connected by a disulfide bond between Cys362 on the 
A4 domain and Cys482 on the catalytic domain. Ile370 (Ile16 in chymotrypsinogen 
numbering) that forms the new N-terminus of the catalytic domain and transits 
approximately 20 Å to form a salt bridge with Asp556 (Asp194 in chymotrypsin 
numbering) that stabilizes the protease oxyanion hole (Navaneetham et al., 2005; 
Papagrigoriou et al., 2006). A similar cleavage between Arg371 and Ile372 activates PK, 
with a predicted shift of 17 Å in the new N-terminus (Hooley et al., 2007). Both PK and 
factor XI are activated by factor XIIa (Davie et al., 1991). However, because factor XII 
deficient people do not have a bleeding disorder, it is not clear that factor XII is the most 
physiologically relevant activator of factor XI. In addition to factor XIIa, factor XI can be 
activated by -thrombin (Naito and Fujikawa, 1991; Gailani and Broze, 1991), the 
prothrombin activation intermediate meizothrombin (von dem Borne et al., 1997), factor 
XIa (autoactivation) (Naito and Fujikawa, 1991; Gailani and Broze, 1991) and trypsin 
(Mannhalter et al., 1980).  Work in progress in our laboratory indicates that -thrombin 
and -thrombin, two degradation products of -thrombin can also activate factor XI.  
 
Activities of Factor XIa 
 -Kallikrein, the active form of PK, is a potent activator of factor XII and cleaves 
HMWK to release bradykinin (Gailani and Broze, 2001).  However, in contrast to factor 
XIa, it is a poor activator of factor IX (Sun and Gailani, 1996).  Factor XIa, is able to 
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cleave factor XII and HK, but with a catalytic efficiency that is far poorer than -
kallikrein. The binding epitopes that confer specificity to the protein-protein interactions 
of factor XI, PK, and their activated forms are likely to be found to a large extent outside 
of the catalytic domains of these molecules.  
 
Apple Domains 
 The structural features setting factor XI and PK apart from other coagulation 
molecules are the apple domains. As discussed in Chapter I, apple domains are members 
of the PAN domain family (Tordai et al., 1999). Apple domains are composed of seven 
-strands that form a curved anti-parallel sheet, with an -helix attached to the concave 
side of the sheet (Figure III-2) (Papagrigoriou et al., 2006). Each end of the -helix is 
attached to the -4 and -5 strands of the -sheet by a disulfide bond. The four apple 
domains of each factor XI subunit are arranged into a planar disc, with 60 X 60 X 20 Å 
dimensions  (Figure III-2).  Two  types of interdomain  interactions are important for the 
packing  stability of apple  domains in  the disc.   These  are referred  to  as  side and edge 
 
Figure III-2. Factor XI 
heavy chain. The apple 
domains of factor XI (A1-
A4) form a planar structure 
measuring 60 by 60 by 20 Å. 
The hydrophobic residues 
and Cys321, which form the 
interface between the dimer 
subunits, are on the loop 
extending from the upper 
right hand corner of A4. 
Image courtesy of J. Emsley 
(Papagrigoriou et al., 2006) 
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interfaces, with reference to the alignment of the -strands composing each apple domain 
(Figure III-2). A1-A2 and A3-A4 domain interfaces are side interfaces, and bury 441 Å2 
and 444 Å2, respectively. The interfaces between A1-A4 and A2-A3 are end interfaces, 
and bury 380 Å2 and 284 Å2, respectively (J Emsley, personal communication).  The 
catalytic domain rests on the planar structure formed by the apple domains, like a "cup in 
a saucer", giving each subunit an overall pyramidal shape (Figure III-1B) (Papagrigoriou 
et al., 2006).  It is likely that PK has a similar structure (Hooley et al., 2007). 
 
Factor XI and Dimerization 
 The major difference between factor XI and PK is that the former is a dimer and 
the latter a monomer. The factor XI A4 domain mediates dimer formation by a mixture of 
hydrophobic interactions and a single disulfide bond involving Cys321 (Meijers et al, 
1992; Papagrigoriou et al., 2006). Cys321 is conserved in factor XI in all mammalian 
species studied with the exception of the rabbit, which has a histidine at this position. Gel 
filtration chromatography shows that rabbit factor XI is in fact a non-covalently 
associated dimer, indicating that non-covalent interactions are sufficient to maintain 
dimeric structure (Sinha et al., 2002). Similarly, human factor XI in which Cys321 has 
been replaced with another amino acid is also a dimer (Meijers et al, 1992; Sinha et al., 
2002; Cheng et al., 2003). 
 The factor XI crystal structure reveals a mixture of electrostatic and hydrophobic 
interactions in the dimer interface. Recent studies have shown that salt bridges and 
hydrophobic interactions are responsible for the relatively tight association constant of 
factor XI subunits in the absence of Cys321 (Samuel et al., 2007). The factor XI dimer 
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subunit interface is 567 Å2, which is about 2.24% of the overall surface area of the factor 
XI monomer (25,312 Å2) (Wu et al., 2008). Most other dimeric proteins have a much 
larger interface, with areas ranging from 3-44% of the total protein surface area. Crystal 
structure studies and mutagenesis work show that the A4 residues Leu284, Ile290 and 
Tyr329 form the relatively small hydrophobic interface between the two subunits 
(Papagrigoriou et al., 2006; Wu et al., 2008).  
 PK cannot form an inter-subunit disulfide bond because Cys321 in its A4 domain 
forms an intrachain disulfide bond with Cys326, which is unique to PK (McMullen et al., 
1991B). In factor XI the residue at position 326 is glycine. However, recombinant PK 
with an unpaired Cys321 (Cys326 changed to Gly) does not form a dimer, indicating other 
components of the A4 domain are required for dimer formation in factor XI (Cheng et al., 
2003). The PK A4 domain does in fact differ from that of factor XI in key residues 
thought to be critical for dimer formation, including residues thought to mediate 
hydrogen bonding (Asn322 to Lys and Gln318 to Pro), residues involved in interfacial salt 
bridges, (Arg345 to Thr and Asp289 to Asn), and residues directly involved in forming the 
interface (Leu284 to Gly and Ser295 to Gly) (Hooley et al., 2007).  
 
Binding Sites on Factor XI and Factor XIa Apple Domains 
 Sites on the apple domains are thought to contribute the majority of binding 
energy for the interactions of factor XI and factor XIa with various ligands and 
substrates. Studies using recombinant factor XI in which individual apple domains were 
replaced by the corresponding domain of PK strongly suggest that factor IX interacts 
with an exosite on the factor XIa A3 domain.  Factor XI with the PK A3 domain (factor 
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XIa/PKA3) supported factor IX activation poorly, with a substantially increased Km for 
the reaction (Sun and Gailani, 1996). Factor IX binds to factor XIa, but does not bind to 
zymogen factor XI (Aktimur et al., 2003). Thus, when factor XI is activated, a 
conformational change must occur that exposes the exosite on the A3 domain. In 
saturation mutagenesis studies, amino acids 183-191 in the factor XIa A3 domain are 
required for factor IX activation (Sun et al., 1999). As expected, these residues are partly 
obscured by the catalytic domain in zymogen factor XI (Figure III-3). Experiments 
demonstrating the importance of the factor XIa A3 domain to interactions with factor IX 
will be shown in Chapters V and VI. Recently, Sinha and colleagues presented evidence 
for another factor IX-binding exosite within the catalytic domain of factor XIa, distinct 
from the protease active site (Sinha et al., 2007). The relative importance of the different 
factor IX-binding exosite on factor XIa is currently under investigation in our laboratory. 
 The factor XI A3 domain also supports interactions with heparin (Zhao et al., 
1998) and the platelet receptor Glycoprotein 1b (GP1b) (Baglia et al., 2004).  A unique 
 
Figure III-3. Putative factor IX 
binding site on the A3 domain. 
Shown is an "edge-on" view of 
zymogen factor XI monomer with 
the end-to-end interface between the 
A2 domain (gray) and the A3 
domain (orange). The catalytic 
domain (green and light blue at top) 
is partially cut away to show an area 
of A3 that is covered by the catalytic 
domain in the zymogen. Arg184 in 
A3 (circled) is required for factor IX 
activation, but is buried in the 
zymogen structure. A salt bridge 
between Arg184 and the catalytic 
domain is probably broken upon 
activation of factor XI, exposing this 
residue to the solvent phase where it 
can participate in factor IX binding. 
Image courtesy of J. Emsley. 
(Papagrigoriou et al., 2006). 
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aspect of the apple domain arrangement of factor XI, that probably holds for factor XIa as 
well, is that it positions the A3 domains of the two subunits on opposite sides of a major 
plane of the molecule (Figure III-4), while the A2 and A4 domains straddle the plane. 
This arrangement has been postulated to have implications for ligand binding 
(Papagrigoriou et al, 2006). For example, a Gp1b platelet receptor could theoretically 
bind to one A3 domain without causing steric interference with factor IX binding at the 
other A3 domain. Both factor XI and PK circulate in plasma bound to HMWK. The A2 
domain in both factor XI and PK is thought to contain a major binding site for HMWK, 
with contributions from the A1 and A4 domains (Renné et al., 2002) via a charged 
“channel” that traverses these domains (Hooley et al., 2007).   
 
Figure III-4. Factor XI. 
View from above the dimer 
interface in the A4 domain 
(yellow). Note that the A3 
domains (orange) are on 
opposite sides of the long 
axis of the molecule 
indicated by the magenta 
line. Catalytic domains are in 
gray. Image courtesy of J. 
Emsley (Papagrigoriou et al., 
2006) 
 
The Importance of the Dimeric Conformation to Factor XI/XIa Function  
 The functional importance of the dimeric structure of factor XI has not been 
resolved, and there has been limited investigation of this issue because of technical 
problems involved in isolating factor XI or factor XIa comprised of a single subunit 
(monomeric factor XI - addressed in Chapter V). Papagrigoriou et al., and later Wu et al., 
suggested a trans-activating mechanism for factor XI activation in which the activating 
protease binds to the apple domains of one factor XI subunit and activates the opposing 
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subunit by cleavage of the Arg369-Ile370 bond (Papagrigoriou et al., 2006; Wu et al., 
2008). The trans-activating mechanism could be a natural consequence of factor XI 
binding to a platelet receptor by one of its subunits, while the other subunit is unbound. 
As discussed in Chapter II, another recent hypothesis regarding the unique dimeric 
structure proposes that factor XIa, which has two active catalytic domains, could cleave 
both scissile bonds on one factor IX molecule simultaneously. This would offer a 
reasonable explanation for why factor XIa activates factor IX without generation of an 
intermediate. Alternatively, if only one factor XIa subunit is required for factor IX 
activation, the other subunit could be involved in tethering the protease to a platelet 
receptor. Most coagulation protease-mediated reactions take place on the surface of 
platelets or TF-bearing cells. The dimeric structure of factor XI/XIa could be an 
adaptation to facilitate this type of binding in a protein that lacks a phospholipid-binding 
Gla domain. 
 
Summary 
 As discussed in Chapter II, factor XIa appears to activate factor IX by a 
mechanism distinct from that used by factor VIIa. It is reasonable to suspect that one or 
more of the unique aspects of the factor XIa structure are responsible for this difference. 
Factor XIa differs markedly in structure from the vitamin K-dependent coagulation 
proteases in several important features including the lack of a Gla domain, the presence 
of apple domains, and its dimeric structure. Because of these differences, it is difficult to 
extrapolate from the structure-function relationships established for the vitamin K-
dependent protease to factor XIa.  The observation that factor XIa can activate factor IX 
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in the absence of a phospholipid surface or a cofactor emphasizes its differences from 
other coagulation proteases, and raises questions as to how it would be regulated in vivo.   
 The fact that factor XI is a homodimer in all mammalian species raises an 
important issue that has only been briefly addressed in the thirty years since the dimeric 
structure was identified (Bouma and Griffin, 1978); that a form of factor XIa may exist 
that is only activated on one of its subunits. In Chapter IV, we examine activation of 
factor XI by factor XIIa and -thrombin in detail, and demonstrate that conversion of 
factor XI to factor XIa proceeds through an intermediate with only one activated subunit. 
This novel species is a valuable reagent for investigating the importance of two activated 
catalytic domains to normal activation of factor IX in Chapter V. 
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CHAPTER IV 
 
DISCOVERY AND PURIFICATION OF A NOVEL FORM OF FACTOR XIa 
 
Introduction 
 During coagulation, factor XI subunits are converted to factor XIa by cleavage of 
the Arg369-Ile370 bond by factor XIIa and various activated forms of thrombin 
(Discussed in Chapter III). Since factor XI is a homodimer, consisting of two identical 
subunits joined by a disulfide bond, it must be cleaved after two spatially separated 
Arg369-Ile370 bonds per molecule for full activation (Figure IV-1). The conversion of 
factor XI to factor XIa has been treated functionally as a simple one-step process, in 
which only fully activated factor XIa is produced. However, it has been postulated that 
factor XI activation should proceed through a singly cleaved intermediate in which one 
subunit is activated, while the other remains uncleaved (Bouma and Griffin, 1978). 
However, no activation time course experiments have been performed that are capable of 
detecting the accumulation of a singly activated form of factor XIa, and only factor XIa 
in  which both subunits are cleaved and activated has been described and characterized in 
 
Figure IV-1. Factor XI 
activation sites. View from 
above the dimer interface in 
the A4 domain (yellow). A3 
domains are in orange, A2s 
in light blue, A1s in dark 
gray. The catalytic domains 
are at the extremes of the 
molecule (light gray).  The 
activation cleavage sites are 
circled in blue. Image 
courtesy of J. Emsley 
(Papagrigoriou et al., 2006) 
  
 51 
existing literature. During factor XI activation, appearance of factor XIa activity is 
typically monitored by cleavage of a chromogenic substrate.  Alternatively, cleavage of 
the Arg369-Ile370 bonds in factor XI can be followed by SDS-polyacrylamide gel 
electrophoresis run under reducing conditions. Reducing conditions have traditionally 
been used to monitor factor XI activation time courses because they show the 
disappearance of the 80,000 Dalton factor XI zymogen subunits, and the appearance of 
the 50,000 Dalton heavy chain (apple domains) and the 30,000 Dalton light chains 
(catalytic domains) (Figure IV-2). Note that neither technique can determine if zymogen 
and activated subunits are on separate molecules (factor XI and factor XIa) or are on the 
same molecule (a half-activated intermediate). Because factor XI does not lose mass 
when converted to factor XIa, there is no reason to expect that electrophoretic migration 
under non-reducing conditions would show a difference between factor XI to factor XIa.  
 
Figure IV-2. Factor XI 
activation. Shown is a 12% 
polyacrylamide gel of samples 
of human factor XI (1.7 μM) 
incubated with factor XIIa 
(0.625) μM. Samples were 
collected into reducing sample 
buffer at the indicated times. 
Positions of zymogen factor XI 
(Z) and the heavy chain (HC) 
and catalytic domain (CD) of 
factor XI are shown on the 
right. Positions of molecular 
mass standards are on the left. 
 
 Our initial efforts to activate plasma-derived human factor XI were intended to 
produce a molecule with two activated subunits. As factor XI is activated slowly in the 
absence of a surface, we used high enzyme:substrate (E:S) ratios so that we could follow 
the progress of activation on conventional stained SDS-polyacrylamide gels. Complete 
 52 
activation of factor XI by either factor XIIa or -thrombin required greater than 24 hours 
of incubation at 37 °C, with E:S ratios as high as 1:1. These prolonged incubation times 
appeared to result in significant degradation of factor XI.  It was our impression that the 
reaction initially proceeded relatively quickly, but then became substantially slower.  
While it is possible that product inhibition was occurring, the observation that it was still 
difficult to drive the reaction to completion at high ES ratios suggested another 
mechanism might be operating. Negatively charged surfaces are typically used to 
enhance activation of plasma factor XI by either factor XIIa or thrombin, and activation 
kinetics are known to be unfavorable in the absence of these surfaces (Gailani and Broze, 
1991; Gailani and Broze, 1993). However, the surface must be removed to generate pure 
factor XIa, and this process was deemed inefficient for use in later experiments. 
 Interestingly, recombinant human factor XI activated by the same protocol was 
fully activated in ~12 hours. We hypothesized that the difference in the observed 
activation rate of recombinant and plasma factor XI could be attributed either to a 
contaminant in the plasma protein that retarded activation, or differences in post-
translational modifications (such as glycosylation) that may render cleavage of the 
second subunit of plasma factor XI more difficult to achieve than cleavage of the first 
subunit.  We were unable to definitively identify an inhibiting contaminant in our plasma 
factor XI preparations. We did, however, observe slight differences in migration between 
standards for factor XI and factor XIa under non-reducing conditions on SDS-
polyacrylamide gels, likely due to changes in protein shape that accompany activation. 
We reasoned that this might provide us with a method for following factor XI activation 
that could detect an intermediate species with only a single activated subunit. 
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 The experiments and data presented in this chapter summarize the discovery of a 
novel, single active site form of activated factor XI that is produced during the activation 
of plasma derived factor XI in solution. This intermediate can be generated by either 
factor XIIa- or -thrombin-catalyzed activation of factor XI. The intermediate, which we 
have designated 1/2-factor XIa, cleaves a chromogenic substrate as efficiently as fully 
active factor XIa when numbers of active sites are normalized. Importantly, 1/2-factor 
XIa can be formed in plasma, suggesting a possible physiologic role for this new enzyme.  
 
Activation of Factor XI by Factor XIIa and -Thrombin 
 As discussed in the previous section, non-reducing SDS gels have not been used 
to follow activation of factor XI. It is reasonable to expect that no change in migration 
would occur upon activation, because no mass is lost from factor XI when it is cleaved by 
either factor XIIa or -thrombin. The negatively charged sodium dodecylsulfate (SDS) 
detergent used in the Laemmli gel electrophoresis system (Laemmli, 1970) coats proteins 
evenly, solubilizing hydrophobic internal amino acids, eliminating secondary and many 
tertiary structures, and allowing the protein to adopt an elongated rod like conformation 
that migrates largely (although not exclusively) based on mass. However, we observed a 
slight difference in mobility between factor XI and factor XIa standards on 12% SDS- 
polyacrylamide gels, and suspected that a lower percentage gel would exaggerate this 
difference. When standards for factor XI and factor XIa were run beside samples from a 
factor XI activation time course on a 6% SDS-polyacrylamide gel, factor XI migrated 
noticeably faster than factor XIa (Figure IV-3). As the actual masses of factor XI and 
factor XIa are the same, this supports the notion that there is a significant shape change 
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upon activation of factor XI. As expected, samples from the activation time-course 
contained bands that migrated with the standards for factor XI and factor XIa, but also 
contained a distinct band that migrated between factor XI and factor XIa (Figure IV-3A). 
Note the rapid disappearance of the zymogen band, but relatively slow disappearance of 
the intermediate band, in keeping with our observation that initial rate of factor XI 
activation is relatively rapid compared to activation later in the time course.  
 
Figure IV-3. Time course 
of factor XI activation by 
factor XIIa. Factor XI (12 
M) in Assay Buffer was 
incubated at 24˚C with factor 
XIIa (860 nM) as described 
under Methods. At various 
times, duplicate aliquots 
were removed into reducing 
and non-reducing sample 
buffer, and fractionated on 
(A) a 12% polyacrylamide-
SDS gel (reducing) or (B) a 
6% polyacrylamide gel run 
(non-reducing), and stained 
with  GelCode  Blue (Pierce,  
Rockford, IL). Migration of standards for unreduced factor XI (FXI), unreduced factor XIa 
(FXIa), reduced factor XI (Z), and the heavy chains (HC) and catalytic domains (CD) of reduced 
factor XIa are shown.  The position of migration of the reaction intermediate is indicated by INT. 
 
 Suspecting that the intermediate band could be a singly cleaved factor XIa 
species, we activated factor XI with factor XIIa and collected samples into reducing and 
non-reducing buffer for gel analysis. We reasoned that if the intermediate band was a 
singly cleaved factor XIa species, its appearance on the non-reducing gel would coincide 
with appearance of the heavy and light chains of factor XIa on the reducing gel. In 
Figure IV-3A the appearance of the intermediate on the non-reducing gel is coincident 
with appearance of the heavy and light chains of factor XIa on a reducing gel (Figure IV-
3B). These complementary time-course gels demonstrate, as discussed above, that 
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traditional reducing gels cannot distinguish between a singly cleaved factor XI species 
(the intermediate) and a mixture of factor XI and factor XIa.  
 The most logical conclusion from these observations was that factor XIa migrates 
more slowly than factor XI through polyacrylamide gels because it has been cleaved at its 
Arg369-Ile370 activation sites. Cleavage after Arg369 could allow each factor XIa subunit 
to adopt a more elongated shape in SDS-containing buffer, or interact differently with 
SDS, than the non-cleaved subunit, increasing the drag that the molecule experiences 
when passing through the pores of a gel. We further reasoned that cleavage after only one 
Arg369 residue would result in a protein that encountered approximately half as much 
drag when passing through the same gel. These experiments cannot be expected to detect 
or predict which factor XI subunit has been cleaved first. Indeed, the crystal structure of 
factor XI indicates that the protein is symmetric around a central axis, and it would not be 
possible to assign a designation to a specific subunit. 
 Factor XI is also activated by -thrombin (Naito and Fujikawa, 1991; Gailani and 
Broze, 1991), giving a similar activation pattern on reducing gels as with factor XIIa 
(Figure IV-4). In our hands, thrombin activation of factor XI is slower than activation by 
factor XIIa, so we used a 1:1 E:S ratio when activating factor XI by -thrombin to 
generate a similar degree of activation to factor XIIa. Factor XI activation by -thrombin 
proceeded through an intermediate. Although the same intermediate is likely to be 
generated with factor XIIa and -thrombin, it is interesting to note that the distribution of 
the intermediate over time is different for the two proteases. The intermediate 
accumulates and persists for a longer period of time in reactions with -thrombin 
compared to factor XIIa, which appears to process the second cleavage more rapidly.  
 56 
 
Figure IV-4. A comparison 
of factor XI activation by 
-thrombin and factor 
XIIa. Plasma factor XI 
(600nM) was incubated at 
37°C with either 600nM -
thrombin or 60 nM factor 
XIIa. Samples of each 
reaction were quenched in 
non-reducing sample buffer 
at the times indicated and 
size fractionated on 6% 
polyacrylamide gels.   
Positions for markers, and 
protein standards for factor 
XI (FXI), factor XIa (FXIa) 
and the activation 
intermediate (INT) are noted. 
 
 We also examined activation of recombinant factor XI by -thrombin. As 
expected, the recombinant material was activated considerably more rapidly than plasma 
factor XI (Figure IV-5), but we still observed formation of the activation intermediate. 
Here  again,  we  see  that  the  initial  cleavage  of  recombinant  factor XI by -thrombin 
appears to be substantially more rapid than the second cleavage.  Our overall impression 
is that the catalytic efficiency for processing the intermediate to factor XIa is higher for 
factor XIIa than for -thrombin. 
 
Figure IV-5. Recombinant 
factor XI activated by -
thrombin. 600 nM factor XI 
was activated by 600 nM -
thrombin. Samples were 
collected into non-reducing 
buffer at the indicated time 
points. Positions for markers, 
and protein standards for 
factor XI (FXI), factor XIa 
(FXIa) and the activation 
intermediate (INT) are noted. 
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Formation of the Factor XI Activation Intermediate in Plasma 
 We wanted to determine if the factor XI activation intermediate observed in the 
purified protein systems described in the previous section could be observed in plasma at 
physiologic protein concentrations. The partial thromboplastin time (PTT) assay is used 
in hospitals to assess plasma coagulation, and it is affected by the levels of all coagulation 
factors with the exception of factor VII/VIIa. The PTT is triggered by contact activation, 
and requires the contact factors factor XII, HMWK, and PK to activate factor XI (Figure 
I-6). The assay uses a negatively charged surface to initiate and propagate the activation 
of factor XII.  In the PTT assay, a substantial portion of the factor XII in plasma is 
converted to factor XIIa, which rapidly converts factor XI to factor XIa. HMWK serves 
as a cofactor to anchor factor XI and PK to the contact surface. 
 We postulated that the factor XI activation intermediate might be formed during 
contact activation in plasma. To test this, we conducted an experiment in which normal 
human plasma, factor XII deficient plasma, or HMWK deficient plasma (Figure IV-6) 
was exposed to a silica-based PTT reagent. Western blots of the resulting activation time 
courses with an anti-human factor XI polyclonal antibody revealed rapid generation of 
both the activation intermediate and factor XIa in normal plasma (Figure IV-6A). As 
expected, no activation pattern was observed in the absence of factor XIIa or HMWK 
(Figure IV-6B and C). The results show that the novel factor XIa activation intermediate 
is generated ex-vivo, albeit in a system that requires an exogenous activator of factor XII. 
It is interesting to note that the appearance of the intermediate and factor XIa and the 
disappearance of factor XI follow the pattern seen in factor XIIa-catalyzed factor XI 
activation reactions in purified systems (Figure IV-4).  
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Figure IV-6. Western blots 
of factor XI activation in 
plasma. (A) Normal human 
plasma, and plasmas lacking 
(B) factor XII or (C) 
HMWK were mixed with a 
PTT reagent at 37˚C. At 
various times, samples were 
removed into non-reducing 
buffer and fractionated on 
6% polyacrylamide gels, 
followed by western blotting 
as described under Methods. 
Positions for markers, and 
protein standards for factor 
XI (FXI), factor XIa (FXIa) 
and activation intermediate 
(INT) are noted. The time 
course is longer for factor 
XII deficient plasma than for 
normal or HMWK deficeint 
plasma. 
 
 
The Factor XI Activation Intermediate Can Cleave a Chromogenic Substrate 
 To confirm the that factor XI activation intermediate described above is an 
activated form of factor XI, we followed the appearance of factor XIa during -thrombin-
catalyzed activation of factor XI, and compared the changes in activity to the appearance 
of factor XI activation products on a western blot (Figure IV-7). The presence of 
activated factor XI was detected by cleavage of the tripeptide chromogenic substrate S-
2366 (see Methods).    Note that  the  rapid   generation  of   protease   activity  correlates  
with  the appearance of the activation intermediate. After a lag phase in which only the 
zymogen and intermediate are seen, there is a further increase in protease activity that 
corresponds to formation of fully activated factor XIa. Based on the observation that 
appearance of the activation intermediate is associated factor XIa protease activity we 
postulated that the intermediate form, indeed, represented a form of activated factor XI in  
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Figure IV-7. Time course of 
factor XI activation by -
thrombin. Factor XI (625 
nM) was activated by 625 nM 
-thrombin. At the indicated 
time points samples were 
tested for (A) factor XIa 
activity by chromogenic 
substrate assay as described 
in methods, or (B) western 
blotting of non-reduced 
samples on a 6% acrylamide 
gel. Positions for markers, 
and protein standards for 
factor XI (FXI), factor XIa 
(FXIa) and activation 
intermediate (INT) are noted. 
 
which only a single subunit was activated (Figure IV-8).  We will refer to this novel 
species hereafter as 1/2-factor XIa. 
 
Purification of 1/2-Factor XIa 
 We developed a method to separate 1/2-factor XIa from factor XI through a 
purification protocol based on the assumption that 1/2-factor XIa has a functional  
 
Figure IV-8. Model for factor XI activation. Factor XI migrates faster than factor XIa on non-
reducing SDS-PAGE. Factor XI activation by -thrombin (above) or factor XIIa (shown) goes 
through an intermediate migrating between factor XI and factor XIa. We predicted that the 
intermediate was factor XI with one activated subunit (1/2-factor XIa). Numbers below the gel 
indicate hours of incubation. In the diagrams, red circles are zymogen, and green three-quarter 
circles activated catalytic domains. A1 - A4 are apple domains. 
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catalytic domain  on one subunit, whereas factor XI does not. This seemed reasonable 
based  on  the  ability  of  1/2-factor  XIa  to  cleave a tripeptide chromogenic substrate. 
We  reasoned  that  if  1/2-factor XIa  was  able  to  cleave  S2366,  then it could also bind 
active site inhibitors that block factor XIa cleavage of this substrate. Benzamidine is a 
small molecule general inhibitor of serine proteases that inhibits factor XIa with an IC50 
of 100 μM (Jin et al., 2005).  Benzamidine binds to the S1 specificity pocket of factor 
XIa with its amidine group forming hydrogen bonds with Asp189, the carbonyl oxygen of 
Gly218 (both chymotrypsinogen numbering) and a conserved water molecule. The 
commercial availability of benzamidine-Sepharose (Sigma, St. Louis) led us to test this 
inhibitor-resin for its ability to bind 1/2-factor XIa, and separate it from zymogen factor 
XI (Figure IV-9).  
 We developed a strategy to produce 1/2-factor XIa with minimal generation of 
factor XIa by using limited digestion of factor XI with -thrombin. Recall that -
thrombin appears to make the cleavage converting 1/2-factor XIa to factor XIa much 
more  slowly  than  does  factor  XIIa.  Time  course  experiments  indicated  that a 1 hour 
 
Figure IV-9. Benzamidine-
Sepharose resin with details of its 
interaction with the factor XIa 
catalytic domain. (A) Schematic 
representation of benzamidine- 
Sepharose resin with the amidine 
group of benzamidine circled in red. 
(B) Crystal structure of recombinant 
factor XIa catalytic domain showing 
the interaction of the amidine group 
of benzamidine (gray ball and stick 
representation) with residues in the 
active site of factor XIa. Asp189 
(D189 in the figure) is at the bottom 
of the protease S1 specificity pocket 
and forms hydrogen bonds with the 
amidine group of benzamidine. 
(After Jin et al., 2005)  
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incubation  of  625  nM  factor XI with 625 nM -thrombin yielded the maximum amount 
of 1/2-factor XIa that could be attained without noticeable contamination by factor XIa 
(Figure IV-10A). When a mixture of factor XI and 1/2-factor XIa was chromatographed 
on benzamidine-Sepharose, 1/2-factor XIa was retained (Schematic diagram below the 
gel in Figure IV-10A), whereas FXI passed through the column and appeared in the flow 
through. 1/2-factor XIa was eluted from the resin by competition with a solution of 100 
mM benzamidine, indicating the band corresponding to 1/2-factor XIa was an active 
protease. Unlike factor XIa, 1/2-factor XIa displayed non-cleaved (zymogen) subunits as 
well as the heavy and light chains of activated factor XI and is, therefore, a species with 
one activated, and one non-activated subunit per factor XI dimer (Figure IV-10B). Note 
that a zymogen factor XI subunit cannot bind to benzamidine unless it is attached to an 
active subunit. The number of moles of active sites per mol of 1/2-factor XIa protein was 
0.93, compared with 1.98 for factor XIa, as determined by active site labeling with an 
excess of the covalent inhibitor fluorescein-Phe-Pro-Arg-CH2Cl. As expected, 1/2-factor 
XIa cleaved S-2366 at about half of the rate (58%) of an equimolar concentration of 
factor XIa (Figure IV-10C). While factor XIa is not seen in the sample in Figure IV-
10B, we did observe traces of factor XIa in some 1/2-factor XIa preparations. 
 
Preparation of Fully Activated Factor XIa with One Inhibited Catalytic Domain 
 The existence of an activated factor XI species with only one active subunit can 
be used as a tool to aid in understanding the importance of the unusual dimeric structure 
of factor XI structure to its function, and in particular as an activator of factor IX. We 
prepared an additional single active site species in which both catalytic domains have
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Figure IV-10. (A) Time course of factor XI activation by -thrombin monitored by SDS-
polyacrylamide gel electrophoresis, and schematic diagram of the generation and 
purification of 1/2-factor XIa and factor XIa-1/2i from plasma factor XI. FXI (625 nM) in 
Assay Buffer (see Methods) was incubated at 37˚C with -thrombin (625 nM).  At various times, 
aliquots were removed into non-reducing sample buffer and fractionated on 6% polyacrylamide-
SDS gels. Migration of protein standards for factor XI (FXI) and factor XIa (FXIa) are shown, 
and migration of the reaction intermediate is indicated by INT. Below the one hr time point on the 
gel are schematic diagrams of factor XI and factor XIa dimers, with ellipses representing heavy 
chains, and circles representing the  catalytic domains. A filled circle  represents an unactivated 
factor XI subunit, an open circle  an activated subunit, and a circle with an "X" () an 
activated subunit in which the active site is inhibited with a chloromethyl-ketone (CMK). To 
prepare 1/2-factor XIa, factor XI undergoes limited activation by thrombin, followed by 
separation of the active species from residual factor XI by chromatography on benzamidine-
Sepharose as described under Methods. Factor XIa with one inhibited active site per dimer (FXIa-
1/2i) was prepared by treating 1/2-factor XIa with CMK to inhibit all active sites.  After dialysis, 
the unactivated subunit of inhibited 1/2-factor XIa was activated by incubation with factor XIIa. 
The final product, factor XIa-1/2i, was separated from traces of inhibited factor XIa by 
chromatography on benzamidine-Sepharose. (B) Purified 1/2-factor XIa. Samples of purified 
factor XI, 1/2-factor XIa, and factor XIa were fractionated under non-reducing conditions on a 
6% polyacrylamide-SDS (top) or reducing conditions on a 12% polyacryalmide-SDS gel 
(bottom), and stained with GelCode blue. (C) 1/2-factor XIa activity in a chromogenic 
substrate assay. Factor XIa () or 1/2-factor XIa () (6 nM) in Assay Buffer containing 500 
mM S-2366 was incubated at 24˚C and changes in absorbance at 405 nm were followed as 
described under Methods. 
 
 
 
 
 
 
 
 
 
 
 
 
 64 
been activated, but in which one of the active catalytic domains has been irreversibly 
inhibited. We call this protease factor XIa-1/2i.  We decided to prepare this protease out 
of concern that 1/2-factor XIa may be converted to factor XIa during subsequent 
experiments with factor IX (discussed in Chapter V). Assuming that there is a significant 
conformational change that accompanies conversion of a factor XI subunit to the active 
form (Samuel et al., 2007), the conformation of factor XIa-1/2i should be the same as for 
factor XIa, but with only one active subunit. Factor XIa-1/2i may, in fact, mimic a form 
of factor XIa found in vivo; that is a factor XIa molecule that has one of its active 
catalytic domains inhibited by a natural protease inhibitor such as antithrombin.  
 We prepared this half-inhibited FXIa using the procedure shown in Figure IV-
10A. Tripeptide chloromethyl-ketone inhibitors are commonly used to covalently inhibit 
serine proteases. We speculated that the activated subunit of 1/2-factor XIa could be 
inhibited by D-Phe-Pro-Arg-CH2Cl, which is used to irreversibly inhibit factor XIa. The 
inhibited 1/2-factor XIa could then be activated on its zymogen subunit, yielding a 
molecule that is conformationally equivalent to factor XIa, but that has half the active 
sites per molecule of factor XIa. 1/2-factor XIa was incubated with D-Phe-Pro-Arg-
CH2Cl. After dialysis, the uncleaved subunit was activated with factor XIIa. The only 
new active sites formed in this step are due to cleavage of the zymogen subunit of /2-
factor XIa. The preparative technique employed prevents contamination of factor XIa-
1/2i with factor XIa. No fully active factor XIa can be generated because zymogen factor 
XI was removed during preparation of 1/2-factor XIa, and any factor XIa in the 1/2-factor 
XIa preparation was inactivated by the chloromethyl ketone. Factor XIa-1/2i has half the 
chromogenic substrate cleavage activity of factor XIa per mole of protein, and is 
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indistinguishable from factor XIa by electrophoresis on 6% non-reducing or 12% 
reducing SDS-polyacrylamide gels.  This protease will be compared to factor XIa and 
1/2-factor XIa in factor IX activation assays described in Chapter V. 
 
Factor XIa/PKA4 
 Availability of monomeric factor XIa would offer another approach to address the 
importance of the dimeric structure of factor XI to factor IX activation. Removing the 
interchain disulfide bond involving Cys321 in the factor XI A4 domain (Figure IV-1) 
does not produce a pure monomeric protein because of the non-covalent interactions 
between the two factor XI subunits (see Chapter III). As discussed, factor XI has a high 
degree of structural homology to PK, which is a monomer. Previously, we described 
recombinant factor XIa in which the A4 domain is replaced with the PK A4 domain (Sun 
and Gailani, 1996). The chimera, factor XIa/PKA4, is a monomer on size exclusion 
chromatography (Figure IV-11) (Cheng et al, 2003). Factor XI/PKA4 is activated 
normally by factor XIIa, and factor XIa/PKA4 cleaves S-2366 and factor IX with similar 
kinetic parameters to factor XIa (Sun and Gailani, 1996).  Factor XIa/PKA4 will be used 
in studies described in Chapter V on factor IX cleavage.  
 
Cleavage of S-2366 by Single Active Site Species of Factor XIa 
 Cleavage of the tripeptide chromogenic substrate S-2366 by 1/2-factor XIa and 
factor XIa-1/2i was compared to factor XIa (Table IV-1). For this study, each active site 
of factor XIa was considered an independent enzyme.  The Kms and kcats for cleavage of 
S-2366 were similar for the three proteases. Previously, we showed that factor XIa/PKA4 
and factor XIa cleaves S-2366 with similar kinetic parameters (Sun and Gailani, 1996). 
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Figure IV-11. Factor 
XI/PKA4. (A) Non-reducing 
12% Polyacrylamide gels of 
recombinant factor XI/PKA4 
(PKA4) in comparison to 
factor XI (FXI) and 
prekallikrein (PK). Note that 
factor XI/PKA4 migrates as 
a monomeric protein, similar 
to PK. (B) Size-exclusion 
chromatography. Twenty 
microgram samples of factor 
XI (red), PK (blue curve) or 
factor XI/PKA4 (green) were 
chromatographed on a 
Superose-12 size-exclusion 
column.  Retention times are 
shown at the bottom and the 
positions of protein 
standards in kilo-Daltons are 
at the top. (C) Amino acids 
299-329 in the A4 domains 
of factor XI and PK. Note 
that Cys321 is unpaired in 
factor XI, and is paired with 
Cys326 in PK. 
 
Properties of Factor XIa Immobilized to Acrylamide Beads by One Active Site  
 Binding interactions of coagulation proteases have been studied by affinity 
chromatography, in which the enzyme to be studied was immobilized specifically by its 
active site to an insoluble matrix (Dharmawardana and Bock, 1998). This work 
demonstrated the utility of immobilized coagulation proteases in studying exosite driven 
interactions.  The  ability  to  selectively  inhibit 1/2-factor XIa on its active site raised the 
 
Table IV-1. Kinetic parameters for cleavage of S-2366 by factor XIa, 1/2-factor XIa, 
and factor XIa1/2i. Values for Km and kcat for S-2366 cleavage were determined by fitting 
the Michaelis-Menten equation to substrate dependence curves using eight concentrations of 
S-2366. Errors in parameters represent 95 % confidence intervals. 
 
Protease Km (μM) kcat (sec-1) 
Factor XIa 440 ± 20 16.1 ± 0.3  
1/2-factor XIa 300 ± 20 12.4 ± 0.3 
Factor XIa-1/2i 340 ± 7 21.6 ± 0.2 
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interesting possibility of using this singly inhibited species, linked to insoluble resin, to 
directly study its macromolecular binding interactions.  
 We activated plasma-derived factor XI with -thrombin to obtain a mixture of 
factor XI and 1/2-factor XIa as described above. The 1/2-factor XIa in the mixture was 
then inhibited by ATA-Phe-Pro-Arg-CH2Cl inhibitor (Bock, 1992A; Bock, 1992B) and 
reacted with iodoacetyl beads by the general reaction strategy illustrated in Figure IV-
12A. This strategy resulted in a homogeneous resin in which the inhibited activate 
subunit of 1/2-factor XIa is linked to the surface of the bead, while the zymogen subunit 
is oriented away from the surface and exposed to the solution phase. When a slurry of 
1/2-factor resin was exposed to reducing SDS-sample buffer and analyzed by reducing 
SDS-gel electrophoresis, the 80kDa zymogen subunit and 50kDa heavy chain of 1/2-
factor XIa were observed on the stained polyacrylamide gels Figure IV-12B. However, 
no light chain was observed, consistent with the catalytic domain of the active subunit 
being covalently linked to the matrix. 
 The free unactivated subunit of the immobilized 1/2-factor XI matrix was 
activated by incubating the matrix with factor XIIa (see Methods). This essentially 
converts 1/2-factor XI resin to factor XIa-1/2i, with the inhibited catalytic domain 
forming the link with the beads. This preparative method eliminates the possibility of 
factor XIa with two active sites being bound to the resin. Factor XIa linked to beads is 
able to use its free catalytic domain to cleave S-2366 (Figure IV-12C). Each microliter 
of beads contributed the equivalent of 3.65 x 10-13 moles of active catalytic domains to 
the assays, as determined by comparison with a factor XIa standard.  This correlates to 
370 nM factor XIa active sites in the packed resin. Assuming each free catalytic domain
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Figure IV-12. 1/2-factor XIa and factor XIa linked to beads. (A) Protocol for linking 1/2-
factor XIa to acryalmide beads. Step 1: The single active catalytic domain of 1/2-factor XIa is 
irreversibly inhibited by incubation with ATA-Phe-Pro-Arg-CH2Cl (Bock, 1992A). > 99% 
inhibition was achieved as determined by a chromogenic substrate assay. Step 2: Inhibited 1/2-
factor XIa is mixed with UltraLink Iodobeads. Step 3: NH2OH is added to initiate the coupling 
reaction. The product, 1/2-factor XIa covalently linked to the beads, presents the unactivated 
subunit of 1/2-factor XIa to the solution phase.  Step 4: 1/2-factor XIa-beads were incubated with 
factor XIIa to activate the zyomgen subunits of the bound protein. In the diagram of the UltraLink 
Iodobeads the cross-hatched area represents a 15 carbon spacer arm.  In the schematic diagrams 
of 1/2-factor XIa the red circle indicates the inactive catalytic domain of the zymogen subunit, 
while the green three-quarter circle indicates the catalytic domain of the activated subunit.  The 
apple domains A1, A2, and A4 are represented by gray ovals, with the A3 domain involved in 
factor IX binding shown as blue oval. (B) SDS-polyacryalmide gel of protein removed from 
1/2-factor XIa-beads with reducing sample buffer.   Ten μl of acryalmide beads linked to 1/2-
factor XIa were mixed with μl of reducing SDS-sample buffer. After removing the beads, the 
sample buffer was size-fractionated on a 10% polyacryalmide-SDS gel and stained with GelCode 
blue. Note that in comparison to standards for factor XI and factor XIa (left lane), the protein 
from the beads (center lane) does not show a band in the position of the factor XIa catalytic 
domain.  This is because the catalytic domain of 1/2-factor XIa is bound to the bead through a 
covalent linkage that cannot be broken by the reducing-sample buffer.  A small amount of bovine 
serum albumin, which was used to block unreacted sites on the beads can be seen in the sample.  
Abbreviations to the left of the panel are (Z) zymogen factor XI subunits, (HC) heavy chain of 
factor XIa subunits, and (CD) catalytic domain of factor XIa subunits.  (C) Hydrolysis of S-2366 
by factor XIa-beads compared to standard factor XIa. In the left-hand panel, factor XIa-beads 
were assayed at a concentration of 3 μl packed resin per ml assay buffer. Cleavage of S-2366 
(500 mM) by this mixture resulted in an increase in absorbance of 0.0047 Au/minute/ul of packed 
resin.  In the right-hand panel factor XIa at 0.01 nM generated an increase in absorbance of 0.022 
Au/minute in the same assay.  
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is not conformationally altered by the inhibited subunit of factor XIa binding to the 
beads, this activity correlates to each microliter of beads contributing 17 ng of active 
factor XIa subunit, or 17 ng factor XIa dimer. This value is in good agreement with the 
quantity of factor XIa observed on reducing gels in which factor XIa removed from resin 
by a reducing buffer was compared with a factor XIa standard. 
 
The Utility of Factor XIa Linked to Beads in Isolating Plasma Binding Partners of Factor 
XI and Factor XIa 
 
 The matrices described in the previous section contain factor XIa derivatives that 
are spatially oriented to present either one factor XI or factor XIa subunit to the 
surrounding solution. This could mimic a physiologic situation in which factor XI or XIa 
is bound to a platelet through one of its subunits, while interacting with macromolecules 
in plasma with the other (Gailani et al, 2001). Factor IX is known to bind to factor XIa, 
but not to factor XI (Aktimur et al., 2003). HMWK binds to factor XI (Thompson et al., 
1977), and probably also binds to factor XIa (Warn-Cramer and Bajaj, 1985). We used 
factor XIa-linked resins to perform pull-down assays from human plasma anticoagulated 
with the thrombin inhibitor hirudin. These experiments were designed to determine 
whether the factor XI or XIa subunits on the factor XIa-resin were in an arrangement that 
would support normal physiologic interactions. It should be noted that the factor XIa 
subunit that is covalently bound to the resin may not be able to bind to other proteins, 
leaving only the free subunit to engage in binding interactions. Beads presenting either 
factor XI or factor XIa to the solution phase bound HMWK (Figure 1V-13A), whereas 
control beads reacted with bovine serum albumin (BSA) did not. Interestingly, factor IX 
did not bind to the free zymogen subunit of 1/2-factor XIa linked to beads (Figure 1V-
 71 
13B), which indicates that factor IX cannot engage the activated subunit covalently 
linked to the bead. This result supports the argument that factor IX can only bind a factor 
XIa subunit that is presented away from a surface to which the protease is bound.  
 
Figure IV-13. Plasma proteins pulled down by factor XIa-beads and 1/2-factor XIa-beads. 
Protein-linked beads (50 μl) were incubated with one ml of normal human plasma for one hour 
at 24°C with rocking.  Beads were pelleted by brief centrifugation in a microfuge and washed 
three times with Assay Buffer (see Methods). After the final wash, beads were mixed with 50 
μl of reducing or non-reducing buffer. Beads were linked to factor XIa (XIa), 1/2-factor XIa 
(1/2) or bovine serum albumin (BSA) (A) GelCode blue stained 12% polyacrylamide gel of 
reduced and non-reduced samples. Positions of proteins that bind to factor XIa and 1/2-factor 
XIa (red arrows) or only factor XIa (green arrows) but not to BSA control are indicated. (B) 
Western blot for unreduced samples. Samples were analyzed by western blotting for HMWK 
or factor IX as indicated.  In both panels BioRad mass standards are indicated by . 
 
Discussion 
 The data presented in this chapter show for the first time that factor XI is 
activated by sequential cleavage of its subunits, proceeding through formation of a half-
activated intermediate that we have called 1/2-factor XIa. Both of the proteases known to 
activate factor XI, factor XIIa and -thrombin, generate 1/2-factor XIa. Both factor XIIa 
and  -thrombin  appear  to  make  the  initial  cleavage  in   factor XI  relatively  quickly, 
however, -thrombin appears to be less efficient than factor XIIa at making the second 
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cleavage that generates fully activated factor XIa. 1/2-factor XIa is generated by factor 
XIIa in normal plasma during contact activation, showing that this reaction can occur in a 
complex environment. Recent studies in our laboratory (Kravtsov et al, manuscript in 
preparation) and work from other laboratories (von dem Borne, 1995) indicate that during 
TF-initiated coagulation, very small amounts of factor XIa are generated, which have a 
profound effect on thrombin generation and fibrin clot stability. Given the small amount 
of factor XIa generated in these assays, and the relatively short time scales of these 
assays, we postulate that the active factor XI species in these experiments is actually 1/2-
factor XIa. 1/2-factor XIa, therefore may represent a physiologic species, or the 
physiologic species of activated factor XI. In a situation where factor XI is bound to the 
surface of a cell or platelet, only one of the subunits might be available for activation, and 
the product would be 1/2-factor XIa.   
 The availability of several factor XIa molecules with single active sites provides 
us with the necessary reagents to test a prevailing hypothesis that factor XIa requires both 
activated catalytic domains to convert a single factor IX molecule to the final product 
factor IXa without formation and/or accumulation of an intermediate (Wolberg et al., 
1997; Samuel et al., 2007). If this hypothesis is correct, then activation of factor IX by 
single active site factor XIa species would be expected to result in factor IX intermediate 
accumulation, or possibly no cleavage at all. If, on the other hand, each factor XIa 
subunit acts independently of the other, then these molecules would be expected to yield 
cleavage patterns similar to factor XIa.  An additional possibility is that 1/2-factor XIa 
could have a unique set of properties related to cooperativity between the subunits. 
Cooperativity could arise when a structural change in the activated subunit of 1/2-factor 
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XIa influences the structure of the zymogen subunit. In this situation, we might expect 
differences in the manners in which 1/2-factor XIa and factor XIa-1/2i interact with 
factor IX. These major issues are addressed in Chapter V, which covers factor IX 
activation by factor XIa. 
 Coagulation proteases in general have domains and/or exosites that facilitate their 
binding to surfaces to localize the reactions they mediate. Studies done under flow 
conditions show that factor XI is crucial for promoting fibrin formation, and that platelets 
are absolutely required to facilitate this process (Tucker et al., 2009). This implies that 
factor XI and/or factor XIa may need to tether to a cell or platelet in order to remain 
properly positioned to contribute to coagulation in flowing blood.  Binding sites for factor 
XI (Walsh 2004) and factor XIa (Sinha et al., 1984) have been identified on platelets. The 
preparations of 1/2-factor XIa and factor XIa bound to beads, therefore, may mimic 
physiologic situations in which factor XI or an activated species are bound to a 
physiologic surface.  The experiments using these reagents demonstrate that they will be 
useful tools for isolating plasma or cellular binding partners of factor XI and factor XIa. 
The image in Figure 1V-13A show that several proteins seem to be interacting with 
factor XI or factor XIa that are not seen in the control BSA beads. 
 Our results so far point to some interesting conclusions.  First, the pull-down 
experiment examining factor IX binding to factor XIa immobilized on beads suggest that 
factor IX may be able to interact with a single factor XIa subunit (addressed in the next 
chapter). In addition, the western blot in Figure 1V-13B indicates that the bound factor 
IX has been converted to factor IXa, strongly suggesting that factor XIa only requires a 
single active subunit to generate the final product.  Whether or not this reaction involves 
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formation and accumulation of an intermediate will be addressed in the next chapter.  
Previous studies of the interaction of HK with factor XI and factor XIa were done in 
buffers that did not have physiologic concentrations of relevant plasma cations (Warn-
Cramer and Bajaj, 1985) or were done in plasma in which divalent cations such as Ca2+ 
were chelated with sodium citrate. Our pull-down assays were done in plasma 
anticoagulated with the thrombin inhibitor hirudin, and thus were done in the presence of 
normal concentrations of all plasma components.  This confirmed the interaction of 
HMWK with factor XI and factor XIa under physiologic conditions. 
 
Methods 
Materials—Factor XIIa, HMWK and corn trypsin inhibitor were purchased from 
Enzyme Research Labs (South Bend, IN). Human -thrombin, factor XIa, and 
fluorescein-Phe-Pro-Arg-CH2Cl were from Hematologic Technologies (Essex Junction, 
VT). Hirudin (Lepirudin) was from Berlex (Wayne, NJ). Benzamidine-Sepharose was 
from Amersham Biosciences (Piscataway, NJ). L-Pyroglutamyl-L-prolyl-L-arginine-p-
nitroanilide (S-2366) was from DiaPharma (West Chester, OH). PTT-A reagent was from 
Diagnostic Stago (Asnières sur Seine, France). Soybean trypsin inhibitor-agarose was 
from Sigma (St. Louis, MO). 
 
Expression and purification of recombinant factor XIa—Recombinant factor XIa was 
prepared as follows. The cDNA for human wild type factor XI (Fujikawa et al., 1986) or 
the chimera factor XI/PKA4 [Sun, 1996] was introduced into a mammalian expression 
vector containing the cytomegalovirus promoter (pJVCMV). 5 x 106 293 fibroblasts were 
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transfected with 40 g of factor XI cDNA/pJVCMV and 2 g of pRSVneo which 
contains a gene conferring neomycin resistance.  Transfection was by electroporation 
using an Electrocell Manipulator 600 (BTX, San Diego).  Transfected cells were grown 
in DMEM with 5% fetal bovine serum for 24 hours, then switched to the same medium 
containing the neomycin analog G418 (500 g/ml).  Media was exchanged every 48 
hours for 14 days.  G418 resistant clones were tested for protein expression by ELISA. 
Clones expressing high levels of protein were expanded in 175 cm2 culture flasks.  When 
cells reached >50% confluence, media was replaced with 75 ml of Cellgro complete 
media containing SBTI (10 g/ml) to prevent activation of factor XI.  Media was 
exchanged every 48 hrs.  After collection, conditioned media was supplemented with 5 
mM benzamidine and stored at -20 oC pending purification. 
 Conditioned media (500-2000 ml) was applied to a 5 ml murine anti-human factor 
XI monoclonal antibody 1G5.12 column (Sun et al., 1999). After loading, columns were 
washed with 10 volumes of 25 mM Tris-HCl pH 7.4, 100 mM NaCl (TBS) and 5 mM 
benzamidine, followed by elution with 2 M sodium thiocyanate in 25 mM Tris-HCl pH 
7.4, 5 mM benzamidine.  Protein containing fractions were pooled and concentrated in an 
ultra-filtration concentrator (Amicon, Inc., Beverly, MA), dialyzed against TBS, and 
stored at -80 oC.  Proteins were analyzed by SDS-polyacrylamide gel electrophoresis for 
purity, and protein concentration was measured by dye binding assay (BioRad, 
Richmond, CA).  Factor XIa was prepared by diluting the zymogen to 100-300 g/ml in 
TBS containing 5 g/ml human factor XIIa and incubating at 37 oC.  Progress of 
conversion of the 80,000 Dalton zymogen to the 50,000 Dalton heavy chain and 30,000 
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Dalton light chain of factor XIa was followed by SDS-polyacrylamide gel 
electrophoresis.  Factor XIa was stored at -80 oC. 
 
Purification of plasma factor XI—Frozen plasma (2 liters) collected in acid-citrate-
dextrose was thawed at 4 °C to induce cryoprecipitation of large proteins, and 
supplemented with benzamidine (20 mM). Factor XI was purified from the 
cryosupernatant by affinity chromatography using the anti-human factor XI antibody 
1G5.12 (Sun et al., 1999). After loading, the column was washed with 50 mM Tris-HCl, 
pH 7.5, 100 mM NaCl, 20 mM benzamidine and eluted with 2 M NaSCN in the same 
buffer. The eluate was concentrated by ultrafiltration and dialyzed against 50 mM Hepes, 
pH 7.4, 125 mM NaCl, 20 mM benzamidine. Purity was assessed by SDS-
polyacrylamide gel electrophoresis and concentration by colorimetric assay (Bio-Rad, 
Richmond, CA). 
 
Hydrolysis of S-2366 by factor XIa— Factor XIa (6 nM active sites, 3 nM protein), 1/2-
factor XIa (6 nM active sites, 6 nM protein), or factor XIa-1/2i (6 nM active sites 6 nM 
protein) were diluted in assay buffer (50 mM Hepes, 125 mM NaCl, 5 mM CaCl2, 0.1 
mg/ml bovine serum albumin) containing 15.6–2000 μM S-2366. Initial rates of 
generation of free p-nitroaniline in 100-μl reaction volumes were measured by 
continuous monitoring of absorbance at 405 nm (3 mm path length) in a SpectraMax 340 
microtiter plate reader (Molecular Devices Corp., Sunnyvale, CA).  
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Western blots of factor XI activation in plasma—Human plasmas anticoagulated with 
0.38% sodium citrate (George King, Overland Park, KS) were mixed with equal volumes 
of PTT A reagent at 37 °C. At various times, 9 μl of reactions were mixed with 6 μl of 
non-reducing sample buffer (233 mM Tris-Cl, pH 6.8, 138 mM SDS, 19% glycerol, 
0.01% bromphenol blue), fractionated on 6% SDS-polyacrylamide gels, and transferred 
to nitrocellulose. The primary antibody was goat anti-human factor XI IgG (Enzyme 
Research Laboratories, South Bend, IN) and the secondary antibody was horseradish 
peroxidase-conjugated anti-goat IgG. Detection was by chemiluminescence. 
 
Preparation of factor XI with a single catalytic active site (1/2-factor XIa)— Plasma 
factor XI (0.6–12 μM) in 50 mM Hepes, pH 7.4, 125 mM NaCl, was subjected to limited 
digestion by incubating with factor XIIa (625 nM) or -thrombin (860 nM) for 1 h at 24 
°C. Reactions were terminated by addition of corn trypsin inhibitor (8.6 μM) or hirudin 
(20μM), respectively. The mixture was applied to a 1 ml benzamidine-Sepharose column.  
After washing with 50 mM Hepes, pH 7.4, 125 mM NaCl, the column was eluted with 50 
mM Hepes, pH 7.4, 125 mM NaCl, 50 mM benzamidine. Factor XI was found in the 
flow through and 1/2-factor XIa in the eluate. 1/2-factor XIa was also prepared by 
chromatography on soybean trypsin inhibitor-agarose. Elution was with 50 mM Hepes, 
pH 7.4, 1 M NaCl, 1 M benzamidine, 1 mM EDTA. The active site concentration for 1/2-
factor XIa was determined by complete inhibition with fluorescein-Phe-Pro-Arg-CH2Cl, 
followed by dialysis to remove free inhibitor. The protein concentration was determined 
by absorbance at 280 nm (corrected for absorbance of the fluorophore) with  of 214,400 
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M-1 cm-1, and the fluorescein concentration was determined by absorbance at 491 nm 
with  of 79,000 M-1 cm-1. 
 
Preparation of factor XIa with one inhibited active site (factor XIa-1/2i)— 1/2-factor 
XIa (2 μM) in 50 mM Hepes, 125 mM NaCl, 1mg/ml polyethylene glycol 8000, pH 7.4, 
was incubated with 20 μM D-Phe-Pro-Arg-CH2Cl at 23°C to irreversibly inhibit active 
sites. Residual inhibitor was removed by dialysis against the same buffer. The 
unactivated subunit of inhibited 1/2-factor XIa was activated by incubation with factor 
XIIa (500 nM) for 7 h at 23 °C. Complete conversion to factor XIa was demonstrated by 
SDS-polyacrylamide gel electrophoresis. Factor XIa-1/2i was separated from residual 
inhibited factor XIa by chromatography on benzamidine-Sepharose.  This also removed 
factor XIIa. 
 
Preparation of factor XIa bound to polyacrylamide beads—Factor XIa bound to 
UltraLink Iodoacetyl Resin (Pierce, Rockford, IL) was prepared by a modification of a 
published method (Dharmawardana and Bock, 1998). 1/2-factor XIa (1 μM) in 50 mM 
Hepes, 125 mM NaCl, 1 mM EDTA, 1 mg/ml polyethylene glycol 8000, pH 7.4 
(coupling buffer), was incubated with 20 μM ATA-Phe-Pro-Arg-CH2Cl (Bock, 1992; 
Dharmawardana and Bock, 1998) to inhibit active sites. After dialysis to remove free 
inhibitor, the dialysate (500 μl) was mixed with 100 μl of packed UltraLink Resin, 
previously washed with coupling buffer. Protein coupling was initiated by addition of 
NH2OH to 0.1 M, and incubation at 24 °C for 4 h with mixing on a rocker. Beads with 
bound protein showed no activity in a chromogenic assay using S-2366, indicating the 
 79 
active sites of bound 1/2-factor XIa were blocked. To generate an active site on the 
uncleaved 1/2-factor XIa subunit, the beads were incubated with factor XIIa (600 nM) at 
37 °C for 6 h with frequent mixing. Unreacted sites were blocked by mixing on a rocker 
with monomeric bovine serum albumin (Dharmawardana and Bock, 1998) (20 mg/ml) 
for 12 h at 24 °C. Specific activity of the reacted beads was determined by cleavage of S-
2366 using factor XIa as a standard. The activity of the packed resin was 370 nM factor 
XIa active sites. 
 
 
References  
 
Aktimur, A., Gabriel, M.A., Gailani, D., and Toomey, J.R. (2003) The factor IX gamma-
carboxyglutamic acid (Gla) domain is involved in interactions between factor IX and 
factor XIa. J Biol Chem 278, 7981-7987. 
 
Bock, P.E. (1992A) Active-site-selective labeling of blood coagulation proteinases with 
fluorescence probes by the use of thioester peptide chloromethyl ketones. I. Specificity of 
thrombin labeling. J Biol Chem 267, 14963-14973. 
 
Bock, P.E. (1992B) Active-site-selective labeling of blood coagulation proteinases with 
fluorescence probes by the use of thioester peptide chloromethyl ketones. II. Properties of 
thrombin derivatives as reporters of prothrombin fragment 2 binding and specificity of 
the labeling approach for other proteinases. J Biol Chem 267, 14974-14981. 
 
Bouma, B.N., and Griffin, J.H. (1977) Human blood coagulation factor XI. Purification, 
properties, and mechanism of activation by activated factor XII. J Biol Chem 252, 6432-
6437. 
 
Cheng, Q., Sun, M-F., Kravtsov, D.V., Aktimur, A., and Gailani, D. (2003) Factor XI 
apple domains and protein dimerization. J Thromb Haemost 1, 2340-2347. 
 
Dharmawardana, K.R, and Bock, P.E. (1998) Demonstration of exosite I-dependent 
interactions of thrombin with human factor V and factor Va involving the factor Va 
heavy chain: analysis by affinity chromatography employing a novel method for active-
site-selective immobilization of serine proteinases. Biochemistry 37, 13143-13152. 
 
Fujikawa, K., Chung, D.W., Hendrickson, L.E., and Davie, E.W. (1986) Amino acid 
sequence of human factor XI, a blood coagulation factor with four tandem repeats that 
are highly homologous with plasma prekallikrein. Biochemistry 25, 2417-2424. 
 80 
Gailani, D., and Broze, G.J. (1991) Factor XI activation in a revised model of blood 
coagulation. Science 253, 909-912.  
 
Gailani, D., and Broze, G.J. (1993) Effects of glycosaminoglycans on factor XI activation 
by thrombin. Blood Coagul Fibrinolysis 4, 15-20. 
 
Gailani, D., Ho, D., Sun, M-F., Cheng, Q., and Walsh, P.N. (2001) Model for a factor IX 
activation complex on blood platelets: dimeric conformation of factor XIa is essential. 
Blood 97, 3117-3122. 
 
Jin, L., Pandey, P., Babine, R.E., Weaver, D.T., Abdel-Meguid, S.S., and  Strickler, J.E. 
(2005) Mutation of surface residues to promote crystallization of activated factor XI as a 
complex with benzamidine: an essential step for the iterative structure-based design of 
factor XI inhibitors. Acta Crystallogr D Biol Crystallogr 61, 1418-1425. 
 
Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the head of 
bacteriophage T4. Nature. 227, 680-685. 
 
Naito, K., and Fujikawa, K. (1991) Activation of human blood coagulation factor XI 
independent of factor XII. Factor XI is activated by thrombin and factor XIa in the 
presence of negatively charged surfaces. J Biol Chem 266, 7353-7358. 
 
Samuel, D., Cheng, H., Riley, P.W., Canutescu, A.A., Nagaswami, C., Weisel, J.W., Bu, 
Z., Walsh, P.N., and Roder, H. (2007) Solution structure of the A4 domain of factor XI 
sheds light on the mechanism of zymogen activation. Proc Natl Acad Sci USA 104, 
15693-15698. 
 
Sinha. D., Seaman, F.S., Koshy, A., Knight, L.C., Walsh. P.N. (1984) Blood coagulation 
factor XIa binds specifically to a site on activated human platelets distinct from that for 
factor XI. J Clin Invest 1984 73, 1550-1556. 
 
Sun, Y., and Gailani, D. (1996) Identification of a factor IX binding site on the third 
apple domain of activated factor XI. J Biol Chem 271, 29023-29028. 
 
Sun, M.F., Zhao, M., and Gailani, D. (1999) Identification of amino acids in the factor XI 
apple 3 domain required for activation of factor IX. J Biol Chem 274, 36373-36378. 
 
Thompson, R.E., Mandle, R., and Kaplan, A.P. (1977) Association of factor XI and high 
molecular weight kininogen in human plasma. J Clin Invest 60, 1376-1380. 
 
Tucker, E.I., Marzec, U.M., Hurst, S., McCarty, O.J.T., Rugonyi, S., Gailani, D., Gruber, 
A., and Hanson, S.R. (2009) Prevention of vascular graft occlusion and thrombus-
associated thrombin generation by inhibition of factor XI. Blood 113,936-944. 
 
 
 
 81 
von dem Borne, P.A., Meijers, J.C., and Bouma, B.N. (1995) Feedback activation of 
factor XI by thrombin in plasma results in additional formation of thrombin that protects 
fibrin clots from fibrinolysis. Blood 86, 3035-3042.   
 
Walsh, P.N. (2004) Platelet coagulation-protein interactions. Semin Thromb Hemost 30, 
461-71. 
 
Warn-Cramer, B.J., and Bajaj, S.P. (1985) Stoichiometry of binding of high molecular 
weight kininogen to factor XI/XIa. Biochem Biophys Res Commun. 133, 417-422. 
 
Wolberg, A.S., Morris, D.P., and Stafford, D.W. (1997) Factor IX activation by factor 
XIa proceeds without release of a free intermediate. Biochemistry 36, 4074-4079. 
 82 
CHAPTER V 
 
FACTOR IX ACTIVATION BY FACTOR XIa 
 
Introduction 
 Previous work on factor IX activation by factor XIa has not dealt directly with the 
mechanistic role that the factor XIa dimer structure plays in the activation of factor IX. 
Wolberg et al (Wolberg et al., 1997) proposed a processive mechanism to explain the 
lack of factor IX intermediate generation by factor XIa. In a processive mechanism, the 
cleavages could be made simultaneously or in succession, but no intermediate would be 
released from the enzyme. In the case of factor XIa it was proposed that the two catalytic 
domains of the dimer could each cleave one of the scissile bonds at either end of the 
factor IX activation peptide, releasing it without generation of an intermediate. As 
discussed, this would be distinctly different from factor IX activation by factor VIIa, 
which has a single catalytic domain. The mechanism used by factor VIIa/TF to activate 
factor IX is best explained by a sequential mechanism, where cleavage at Arg145-Ala146 
to generate factor IX occurs prior to cleavage at Arg180-Val181 to form factor IXa 
(Osterud and Rapaport, 1977; Bajaj et al., 1983; Lawson and Mann, 1991) (Figure V-1).  
 An argument against a processive mechanism for factor IX activation by factor 
XIa can be made based on the relative positions of the factor XIa two catalytic domains 
in the crystal structure of zymogen factor XI (Papagrigoriou et al., 2006), which are too 
far apart to simultaneously engage a single factor IX molecule. Recent, nuclear magnetic 
resonance  work  with  isolated  factor  XI  A4  domains  suggested  that  cleavage  at  the  
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Figure V-1. Time courses of factor IX activation by factor VIIa and factor XIa monitored 
by western blotting. (A) Factor IX is cleaved after Arg145 and Arg180 to release the activation 
peptide (green ribbon) and produce the active protease factor IXa.  Initial cleavage after Arg145 
separates the light chain (Gla and EGF domains) and the N-terminus of the AP, producing the 
intermediate factor IX. This is the preferred pathway for factor IX activation by factor VIIa/TF 
(bold solid arrows).  Cleavage initially after Arg180 results in separation of the factor catalytic 
domain (CAT) from the C-terminus of the AP, generating a partially active intermediate, (factor 
IXa. (B-D) Factor IX (100 nM) in Assay Buffer (see Methods) was incubated at 24 ˚C with 1 
nM factor VIIa in the presence of saturating TF (B) or 1 nM active sites of two different 
preparations of factor XIa (C and D). Aliquots were removed at indicated reaction times into 
denaturing reducing buffer, fractionated on 12% polyacrylamide-SDS gels, and analyzed by 
western blotting as described under Methods. Migration of protein standards for zymogen factor 
IX (FIX), the large fragment of factor IX (FIX), the large fragment of factor IXa, the heavy 
chain of factor IXa or factor IXa (HC), and the light chain of factor IXa or factor IX (LC). 
 84 
Arg369-Ile370  bond  converting  factor XI  to factor XIa results in a structural change that 
probably alters the relationship of the two catalytic domains to each other (Samuel et 
al.,2007). Electron microscopy studies using rotary shadowing techniques do indicate a 
significant change in overall protein conformation when factor XI is converted to factor 
XIa (Samuel et al., 2007), possibly moving the catalytic domains sufficiently close to 
each other so that they would be able to engage each end of the activation peptide of a 
single factor IX molecule.  
 Previously, we showed that the monomeric variant factor XIa/PKA4 (see Chapter 
IV) can activate factor IX with similar kinetic parameters to activation by factor XIa (Sun 
and Gailani, 1996). However, it is not known if an intermediate is generated in this 
reaction. If a processive mechanism involving both factor XIa catalytic domains is 
required for activation of factor IX without accumulation of an intermediate, then 
molecules such as factor XIa/PKA4, 1/2-factor XIa, and factor XIa-1/2i should 
presumably cleave factor IX in a manner similar to factor VIIa; that is by cleaving the 
protein at one bond to generate an intermediate. The experiments in this chapter were 
designed to test the hypothesis that factor XIa needs two activated catalytic domains per 
molecule to activate factor IX normally, without releasing one of the two possible 
intermediates factor IX or factor IXa (Figure V-1).  
 We show here that factor XIa with one active catalytic domain per molecule 
activates factor IX without accumulation of either possible singly cleaved factor IX 
intermediate, and that the mechanism involved cannot be explained by cooperativity 
between factor XIa subunits within a molecule or between two factor XIa molecules. We 
also demonstrate that factor XIa with both subunits activated binds two factor IX or 
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factor IXa molecules, implying that each factor XIa subunit is capable of acting as an 
individual enzyme toward its substrate that can be inhibited by its product.  
 
Kinetic Parameters of Factor IX Activation by Factor XIa 
 As shown in Chapter IV, the kinetic parameters for cleavage of tripeptide 
substrate S-2366 by factor XIa and single active site species of factor XIa are similar on 
an active basis. This experiment established that the catalytic domains are in the expected 
active conformation in these proteases, and that there are no significant alterations in the 
conformations of the active sites.  Next, we studied the kinetics of factor IX activation by 
factor XIa using a chromogenic substrate assay (Ogawa et al., 2005). Initial rates of 
activation were determined from analysis of full progress curves and from the factor IX 
dependence   of  the   initial  rate  of  factor  IXa  formation  (Figure  V-2).   The results, 
summarized  in  Table V-1,  indicate  that  factor XIa and its singly active site derivatives  
 
Figure V-2. Factor IX 
activation by factor XIa, 
1/2-factor XIa and 
factor XIa-1/2i followed 
by chromogenic assay.  
Factor IX at 25 nM (), 
50 nM (), 100 nM (), 
250 nM (), 500 nM 
(), or 1000 nM () in 
Assay Buffer was 
incubated at 24˚C with 1-
10 nM of active site of 
(A) Factor XIa, (B) 1/2-
factor XIa, or (C) factor 
XIa1/2i. At appropriate 
time points aliquots were 
assayed for factor IXa 
activity     as      described  
under Methods. (D) The initial rates for activation of factor IX (25-1000 nM) by factor XIa (), 
1/2-factor XIa (), and factor XIa1/2i () for factor IX were determined from the progress 
curves in A-C as described under Methods, and are plotted as a function of initial factor IX 
concentration in each reaction. 
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Table V-1. Kinetic parameters for activation of factor IX by factor XIa, 1/2-factor 
XIa, and factor XIa-1/2i. Km and kcat for factor IX activation were based on initial rates for 
factor IX activation from full progress curves (Fig. V-2) as described under Methods.  The 
resulting vo values were analyzed by fitting the Michaelis-Menten equation, and values for Km and 
kcat were obtained from direct non-linear least squares analysis. Values for Km and kcat were used 
to analyze the complete progress curves by the integrated Michaelis-Menten equation. With 
values for Km and kcat fixed, full progress curves were fitted simultaneously by the integrated rate 
equation with product inhibition to obtain estimates of Ki for factor IXa. Errors in parameters 
represent 95 % confidence intervals. 
 
Protease Km (nM) kcat (min-1) Ki (nM) 
Factor XIa 53 ± 8 33 ± 1 23 ± 46 
1/2-factor XIa 90 ± 40 28 ± 3 23 ± 26 
Factor XIa-1/2i 90 ± 30 23 ± 2 18 ± 23 
 
 
have similar apparent affinities (Km) and turnover numbers (kcat) for factor IX. The 
results for 1/2-Factor XIa are unlikely to be due to contaminating factor XIa. If 1/2-factor 
XIa (the vast majority of protease in the preparation) did not cleave factor IX, and all 
factor IX activation was due to traces of factor XIa, the turnover number (kcat) would be 
very low relative to the factor XIa control. Previously, our laboratory demonstrated that 
factor IX and factor IXa bind to factor XIa in a mutually exclusive manner, and that the 
Ki for product inhibition and the Km for factor IX activation are similar (Ogawa et al., 
2005). In the present studies, the Ki values for product inhibition were similar for factor 
XIa, 1/2-factor XIa, and factor XIa-1/2i (Table V-1), and were reasonably similar to Km 
values, given the techniques used. The results indicate that factor XIa and its single active 
site derivatives bind to and activate factor IX similarly. The results are consistent with the 
observation that monomeric factor XIa/PKA4 activates factor IX with similar kinetic 
parameters to factor XIa (Sun and Gailani, 1996) 
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Single Active Site Factor XIa Species Have Activity in Plasma Clotting Assays 
 As described in Chapter IV, 1/2-factor XIa is formed in plasma induced to 
undergo contact activation, suggesting it may also be formed in vivo as part of normal 
physiology. Since factor XIa contributes to fibrin clot formation and maintenance by 
activating factor IX, and half active forms of factor XIa appear to activate factor IX 
similarly to factor XIa, we predicted that these species would have procoagulant activity 
in plasma. To determine if 1/2-factor XIa and factor XIa-1/2i can induce coagulation, the 
enzymes were compared with factor XIa in a clot formation assay. In this assay, 
preparations of the proteases and phospholipid were added to factor XI deficient plasma 
anticoagulated with the calcium chelator sodium citrate, which was then triggered to form 
a clot by addition of calcium to reverse the anticoagulation. Formation of a clot after 
addition of calcium is monitored by changes in viscosity of the plasma over time using a 
fibrometer. The relative activities of 1/2-factor XIa (102%) and factor XIa-1/2i (130%) 
were comparable to fully active factor XIa (activity arbitrarily set at 100%) when 
corrected for the number of active sites per molecule. Again, these results are consistent 
with those previously generated with the factor XIa/PKA4 (Sun and Gailani, 1996). 
These results demonstrate that activated factor XI with a single active site is capable of 
inducing plasma to form a clot, almost certainly through activation of factor IX.  
 
Single Active Site Factor XIa Cleaves Factor IX Without Intermediate Generation 
 The time courses of factor IX activation by factor VIIa/TF and factor XIa shown 
in Figure V-1 clearly demonstrate the different patterns of cleavage produced by the two 
proteases. Time courses of factor IX activation by the single active site factor XIa species 
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1/2-factor IXa, factor XIa-1/2i and factor XIa/PKA4 were analyzed by the same western 
blotting technique (Figure V-3). The data convincingly show that factor XIa with only 
one active catalytic domain per molecule is capable of making both activation cleavages 
in factor IX without significant accumulation of activation intermediates, in contrast to 
reactions with factor VIIa/TF as the activating enzyme. While a slight accumulation of 
factor IX was seen in the activation time courses catalyzed by 1/2-factor IXa and factor 
XIa-1/2i, it did not accumulate, and was also seen in the starting material.  This is 
occasionally seen in activation time courses with fully active factor XIa (Figure V-1D). 
In Figure V-3C, the activating enzyme is the monomer factor XIa/PKA4. There is slight 
accumulation of factor IX with this protease, but note that it appears simultaneously 
with the formation of factor IXa, and not prior to it as is seen with factor VIIa/TF. 
 Again, the results with 1/2-factor XIa cannot be explained by traces of 
contaminating  factor  XIa  in  the  preparation,  as  demonstrated  by consideration of the 
 
Figure V-3. Time courses 
of factor IX activation by 
single active site factor 
XIa species monitored by 
western blotting. Factor 
IX (100 nM) in Assay 
Buffer was incubated at 
24˚C with 2 nM (active 
sites) (A) 1/2-factor XIa, 
(B) factor XIa1/2i, or (C) 
factor XIa/PKA4. Aliquots 
were removed at indicated 
times into reducing sample 
buffer, fractionated on 
12% polyacrylamide-SDS 
gels, and analyzed by 
western blotting as  shown  
in the Methods section.  Migration of protein standards is shown for zymogen factor IX (FIX), the 
large fragment of factor IX (FIX), the large fragment of factor IXa, the heavy chain of factor 
IXa or factor IXa (HC), and the light chain of factor IXa or factor IX (LC).  There was a 
defect in the well for the three minute sample for 1/2-factor XIa (A), which resulted in an 
abnormal pattern of electrophoresis. 
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following scenarios. If two factor XIa active sites are required for normal factor IX 
cleavage, intermediate will accumulate when 1/2-Factor XIa cleaves factor IX and should 
be seen on the western blots, even if a trace of factor XIa activates some factor IX. This is 
because the vast majority of protease is 1/2-factor XIa. Alternatively, 1/2-Factor XIa may 
not cleave factor IX at all, and all factor IX activation could be through factor XIa. We 
would not expect the intermediate to accumulate in this situation; however, the rate of 
factor IX activation would be significantly reduced relative to the factor XIa control. This 
was not evident in Figure V-3A. In the case of factor XIa-1/2i, which is a dimer with one 
functional and one blocked active site, the method used to prepare the enzyme makes 
contamination with either factor XI or factor XIa highly unlikely, and factor IX activation 
must be through the single active site species.  These results are not consistent with a 
model in which both catalytic domains of factor XIa are required for normal activation of 
factor IX, and suggest that each factor XIa molecule is comprised of two complete 
enzymes that likely function independently of each other.  
 
Activation of Factor IX by Factor XIa Linked to a Surface by One of Its Active Sites 
 The results in the previous section rule out a processive mechanism for factor IX 
activation that require two active sites per factor XIa molecule, and strongly favors a 
mechanism in which each factor XIa subunit is independently capable of activating factor 
IX. An alternative possibility that could be consistent with a processive mechanism 
requiring two factor XIa catalytic domains would involve cooperativity between separate 
factor XIa molecules. This mechanism would involve factor IX engaging a factor XIa 
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subunit, which would cleave one scissile bond in factor IX, with the second bond cleaved 
by an active subunit of another factor XIa molecule.  
 Factor XIa linked to acrylamide beads, as described in Chapter IV, cannot freely 
diffuse across the surface of the bead and, therefore, may be in a situation somewhat 
analogous to the single catalytic domain of factor VIIa in complex with tissue factor at a 
site of vascular injury. We activated 100 nM factor IX with factor XIa linked to beads 
with 1 nM equivalent factor XIa catalytic activity, and the time course was followed by 
western blotting (Figure V-4). No factor IX intermediate accumulated in this reaction, 
which appeared to progress at roughly the same rate as with factor XIa in solution. These 
results show that factor XIa can cleave factor IX normally in a surface bound orientation 
with only one active subunit available. The results are also consistent with those with 
single active  site species of factor XIa in solution, but suggest that cooperativity between 
two separate factor XIa molecules is unlikely. The results still leave open the possibility 
that   each  free   subunit  of   factor  XIa   makes  both   cleavages  in  factor  IX  without 
 
 
Figure V-4. Time course of factor IX 
activation by factor XIa immobilized on 
polyacrylamide beads monitored by 
western blotting. Factor IX (100 nM) in 
Assay Buffer was incubated at 24˚C with 2 
nM active sites of (A) factor XIa or (B)  
factor XIa linked to polyacrylamide beads 
through a chloromethyl ketone inhibitor 
occupying one of the active sites. Aliquots 
were removed at indicated times into 
denaturing reducing buffer, fractionated on 
12% polyacrylamide-SDS gels, and 
analyzed by western blotting as described 
under Methods. Migration of protein 
standards is shown for zymogen factor IX 
(FIX), the heavy chain of factor IXa 
(HC), and the light chain of factor IXa 
(LC).  
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intermediate release (a processive mechanism).  This will be addressed in the next 
experiment. 
 
The Effect of Active Site Inhibited Factor XIa (Factor XIai) on Factor IX Activation 
 Data from the preceding experiments supports a model in which each subunit of 
factor XIa behaves as an independent enzyme.  The mechanism for factor IX activation, 
therefore, likely involves an interaction between the substrate and only one factor XIa 
subunit. It seems unlikely that a molecule with a single active site, such as a subunit of 
factor XIa, would operate by a true processive mechanism. Processive mechanisms are 
typically employed by larger enzymes that partially or fully enclose the substrate 
molecule to be cleaved, and that often have multiple active sites (Breyer and Matthews, 
2001). The crystal structures of factor XI, and the structural predictions pertaining to its 
activation, do not indicate factor XIa would operate by a true processive mechanism.  
 The initial interaction of factor IX with factor XIa involves one or more exosites 
on the factor XIa heavy chain that should also be available on factor XIa with an inhibitor 
in its active sites (factor XIai). Factor XIai should, therefore, compete with factor XIa for 
binding to factor IX, behaving as a competitive inhibitor of factor IX activation. We 
reasoned that factor XIai would also compete with factor XIa binding to factor IX, if 
this intermediate was released, and would trap that intermediate in a non-productive 
complex. This should result in accumulation of factor IX during an activation time 
course.  
 When factor IX was activated by factor XIa in the presence of 1000-fold molar 
excess  of factor XIai, we observed a reduction in the rate of zymogen factor IX cleavage,  
 92 
 
Figure V-5. Time course of factor IX 
activation by factor XIa in the 
presence of factor XIai monitored by 
western blotting. Factor IX (100 nM) in 
Assay Buffer was incubated at 24˚C with 
2 nM active sites of factor XIa in the (A) 
absence or (B) presence of 1000 nM 
factor XIai. Aliquots were removed at 
indicated reaction times into reducing 
buffer, fractionated on 12% poly-
acrylamide-SDS gels, and analyzed by 
western blotting as described Methods. 
Note that sampling times differ for the 
two reactions. Migration of protein 
standards is shown for zymogen factor 
IX (FIX), the large fragment of factor 
IX (FIX), the heavy chain of factor 
IXa (HC), and the light chain of factor 
IXa (LC).  
 
as expected in the presence of an inhibitor (Figure V-5).  In addition, there was a 
significant accumulation of factor IX in a pattern similar to that observed with factor 
VIIa catalyzed activations. This result strongly suggests that factor XIa initially cleaves 
the factor IX Arg145-Ala146 bond to form factor IX, and that factor IX is released from 
factor XIa and is available to bind to factor XIai. To complete conversion to factor IXa, 
factor IX must rebind to factor XIa, followed by cleavage of the Arg180-Val181 bond. 
Therefore, in addition to competing with factor XIa for binding to factor IX, factor XIai 
also appears to compete for binding to factor IX. The result argues against a mechanism 
for factor IX activation where both activation sites on factor IX are cleaved without 
release of an intermediate (the processive mechanism), and indicates that the Arg145-
Ala146 and Arg180-Val181 bonds in factor IX are cleaved sequentially by each factor XIa 
subunit. It is important to note that while these results demonstrate the likely order of 
bond cleavage by factor XIa, they do not predict which bond represents the rate limiting 
cleavage. However, given the lack of factor IX accumulation during activation by factor 
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XIa in the absence of an inhibitor, one could predict that the second cleavage at the 
Arg180-Val181 must be at least as rapid as the initial cleavage.  This issue will be 
addressed in Chapter VI. 
 
Activation of Factor IX by the Isolated Catalytic Domain of Factor XIa (Factor XIa-CD)  
 To determine the importance of the heavy chain exosites on factor XIa in factor 
IX activation, we prepared recombinant isolated factor XIa catalytic domain (factor XIa-
CD). This was achieved using recombinant factor XI in which Cys362 and Cys482 are 
replaced by serine residues (factor XI-Ser362,482). These residues form the disulfide bond 
that connects the catalytic domain to the heavy chain in factor XIa (see Figure III-1). 
When factor XI-Ser362,482 is converted to the active protease by incubation with factor 
XIIa, the catalytic domain dissociates from the heavy chains, and can be purified. The 
resulting factor XIa-CD cleaves a chromogenic substrate similarly to factor XIa, but is a 
poor activator of factor IX, likely due to the loss of substrate binding exosites on the 
heavy chain (Ogawa et al., 2005). Recently, Sinha et al. showed that factor XIa-CD 
cleaved factor IX with accumulation of factor IX (Sinha et al., 2007). In these studies, 
which used stained gels and high substrate concentrations, factor IX was also evident 
during factor IX activation by wild type full-length factor XIa.  
 We activated a physiologic concentration of factor IX (100 nM) with a high 
concentration of Factor XIa-CD (50 nM) and also observed significant accumulation of 
factor IX (Figure V-6A). The result is distinctly different from those for the other single 
active site factor XIa species described above, and indicates that the mechanism by which 
factor XIa subunits activate factor IX with limited intermediate accumulation requires the  
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Figure V-6. Time courses of factor IX 
activation by factor XIa-CD monitored 
by western blotting. Factor IX (100 nM) 
in Assay Buffer was incubated at 24˚C 
with factor XIa-CD (A) 50 nM active 
sites or (B), or 2 nM active sites. 
Aliquots were removed at indicated 
reaction times into denaturing reducing 
buffer, fractionated on 12% 
polyacrylamide-SDS gels, and analyzed 
by western blotting as described under 
Methods. Note that the sampling times 
differ for the two reactions. Migration of 
protein standards is shown for zymogen 
factor IX (FIX), the large fragment of 
factor IX (FIX), the heavy chain of 
factor IXa (HC), and the light chain of 
factor IXa or factor IX (LC). 
 
 
factor XIa heavy chain. Activation of factor IX at the typical 100 nM physiologic 
concentration with 2 nM equivalent factor XIa-CD active sites (an enzyme concentration 
comparable to that used in the time courses in Figure V-3) resulted in extremely slow 
conversion of  factor  IX to  factor IX (Figure V-6B), likely caused by an increased Km 
due to lack of sufficient binding energy at physiologic concentrations. These results 
indicate that, at concentrations relevant to physiologic conditions, the binding energy 
needed to tether factor IX to factor XIa is provided by exosites in the heavy chain of each 
factor XIa subunit.  
 These results clearly show that factor XIa-CD cleaves the factor IX Arg145-
Ala146  bond before it cleaves the Arg180-Val181 bond. This suggests that the factor XIa 
heavy chain would normally orient factor IX in a position that facilitates cleavage after 
Arg180. Taken together with the data from the factor XIai inhibition study (above), it 
appears that factor XIa subunits cleave the factor IX Arg145-Ala146 and Arg180-Val181 
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bonds sequentially, with the heavy chain tethering factor IX in position to cleave after 
Arg180 efficiently.  The heavy chain also appears to be critical for the initial binding of 
factor IX to the protease as the cleavage of the Arg145-Ala146 bond is significantly slower 
with factor XIa-CD compared to factor XIa.  
 
Titration of Active Site-Labeled Factor XIa by Factor IX and Factor IXa 
 The data presented so far strongly indicate that each factor XIa subunit behaves as 
a complete enzyme toward factor IX. Each factor XIa dimer, therefore, should bind two 
factor IX molecules. Factor XIa was inhibited with a tripeptide chloromethyl-ketone 
linked to a fluorescent dansyl group that functions as a reporter of change in the 
microenvironment around the factor XIa active site (Warn-Cramer and Bajaj, 1985). The 
fluorescence probe is covalently linked via the chloromethyl ketone to the active site 
catalytic histidine and serine residues (Figure V-7A). Because initial binding of factor IX 
to factor XIa involves interactions with exosites remote from the active site (Ogawa et 
al., 2005), blocking the active site should not significantly affect factor IX binding to the 
active site inhibited factor XIa. Titration of active site-labeled factor XIa with factor IX 
resulted in increased fluorescence (Figure V-7B), with a maximum enhancement at 
saturation of 43 ± 3%, and a stoichiometry of 1.9 ± 0.4 mol of factor IX per mol of factor 
XIa. The Kd for the interaction (70 nM ± 40 nM) was consistent with published results 
(Aktimur et al., 2003; Ogawa et al.,  2005).  The  observed  smooth  increase  in  
fluorescence  with  addition of factor IX suggested there was no intra-subunit 
cooperativity,  where  binding  to one  subunit  confers  a change in binding affinity to the 
other subunit.  Earlier  work  showed that factor IX and factor IXa have similar affinities 
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Figure V-7. Titration of active site-labeled factor 
XIa with factor IX and factor IXa . (A) Two 
micrograms of unlabeled factor XIa (U) or factor 
XIa inhibited with 1,5-Dansyl-Glu-Gly-Arg-CH2Cl 
(L) were fractionated on 12% poly-acrylamide-
SDS gels under non-reducing (left)  or  reducing 
(center) conditions, and stained with GelCode Blue. 
Prior to staining, gels were photographed under 
ultraviolet light (right).  Note that the fluorescent 
Dansyl probe has been appropriately incorporated 
into the factor XIa catalytic domain. Migration of 
protein standards for unreduced  factor  XIa  (XIa),  
the  heavy  chain  of reduced factor XIa (HC),  and  
the catalytic domain of reduced factor XIa (CD) are shown. (B and C) Fluorescence titrations of 
Dansyl-labeled factor XIa (100 nM [], 500 nM [] or 1000 nM []) with factor IX (A) or 
factor IXa (B) were performed as described under Methods.  The solid lines represent the 
nonlinear least-squares fits by the quadratic binding equation with the parameters given in the 
text. 
 
for factor XIa (Ogawa et al., 2005). Binding of factor IXa to labeled factor XIa 
increased the fluorescence to a maximum of 23 ± 1% (Figure V-7C), again with no 
evidence of cooperativity. The stoichiometry of factor IXa binding to factor XIa was 
approximately 2:1 (2.2 ± 0.4), with a Kd of 100 ± 50 nM. The results support the 
conclusion that each half of the factor XIa dimer can function as a complete enzyme 
toward factor IX in solution. 
 
 
 
A 
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Discussion  
 The data presented in this chapter show that each subunit of factor XIa behaves as 
an independent enzyme toward its physiologic substrate, factor IX. Previously, it has 
been assumed that factor XIa formed during coagulation has both subunits activated, and 
this is the only form that has been studied in detail. Furthermore, it was postulated that 
the mechanism by which factor XIa activates factor IX is dependent on factor XIa having 
two active subunits, allowing processive cleavage of the two scissile bonds in factor IX. 
Our discovery of 1/2-factor XIa that is cleaved at the Arg369-Ile370 activation site on only 
one subunit allowed us to investigate the importance of the unique dimeric structure to 
protease function. The observation that 1/2-factor XIa can be generated in plasma, and 
the ability of this protease to initiate clot formation in plasma indicates that it contributes 
to factor IX activation under physiologic conditions. Our data directly address two 
hypotheses put forward in the literature; that factor XIa uses a processive mechanism to 
activate factor IX without intermediate generation, and that factor VIIa and factor XIa 
activate factor IX by different mechanisms.  
 The assumption that all factor XIa formed in plasma has two active catalytic 
domains per molecule allowed the construction of a reasonable hypothesis to explain the 
mechanism by which factor IX is cleaved at two distinct sites without accumulation of an 
intermediate. Our studies with single active site factor XIa proteases refute this attractive 
hypothesis.  Our kinetic data confirm that factor XIa with a single active site, or with both 
subunits activated, converts factor IX to factor XIa at comparable rates, indicating each 
subunit is sufficient for normal activation of factor IX. We constructed factor XIa linked 
to acrylamide beads to reduce the likelihood that two factor XIa molecules could interact 
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with one factor IX molecule to cleave the Arg145-Ala146 and Arg180-Val181 
cooperatively. This is an important consideration since factor XIa, unlike other 
coagulation proteases, is not known to associate with a phospholipid surface or surface-
bound co-factor and is, therefore, presumably free to activate factor IX in solution. These 
results indicated that, if factor XIa uses a true processive mechanism to convert factor IX 
to factor IXa, that mechanism is contained within one subunit of the dimer.  
 Since factor XIa requires only one catalytic subunit to make both cleavages in 
factor IX, we thought it likely that one cleavage would be made initially, as with factor 
VIIa/tissue factor, and that a processive mechanism was unlikely. We postulated that the 
reason factor IX accumulates during activation by factor VIIa/tissue factor is because 
cleavage after Arg180 is rate-limiting. In contrast, if a sequential cleavage mechanism 
was operating, factor XIa would need to make its rate limiting cleavage first to explain 
the lack of intermediate accumulation (Osterud et al., 1978). Factor XIai was used as a 
“trap” to bind and retain intermediates released during factor IX activation. When factor 
IX was activated by factor XIa in the presence of a 1000-fold molar excess of factor XIai, 
a large amount of factor IX accumulated, indicating factor XIa makes its initial cleavage 
after Arg145. If factor IX is released from factor XIa, one might expect that it should 
accumulate early during time course reactions if it binds to a similar exosite on factor XIa 
as zymogen factor IX. This is because, early in the reaction, factor IX is in vast excess of 
factor IX, as factor XIai was in our experiment. That this is not observed raises the 
possibility that factor IX and factor IX may bind to factor XIa at different sites (not in a 
mutually exclusive manner as one would expect for a competitive inhibitor). Indeed, we 
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noted that a fairly high concentration of factor XIai is required to observe factor IX 
accumulation in the time course experiments.   
 Many symmetrical enzymes with multiple identical catalytic sites display 
cooperativity. Binding curves did not show evidence of cooperativity between factor XIa 
subunits. Cooperativity could involve binding of factor IX to one subunit enhancing 
binding of another factor IX to the opposite subunit. A titration of this type of enzyme 
would be sigmoidal, reflecting the lower affinity valence being occupied first. The 
opposite form of cooperativity would involve factor IX binding to one subunit lowering 
the affinity for binding to the opposite subunit, either by allosteric structural 
rearrangement or by steric hindrance by the initial binding factor IX. Our data indicates 
each factor XIa subunit binds factor IX or factor IXa independently of the other.  
 Exosite interactions are important for initial recognition of a substrate by a 
coagulation protease (Krishnaswamy, 2004; Bock et al., 2007). The factor XIa heavy 
chain appears to be responsible for most if not all exosite binding energy in the factor 
IX/factor XIa complex (Sun and Gailani, 1996; Ogawa et al., 2005). We activated factor 
IX with factor XIa-CD, which has no heavy chain, to determine the role of the heavy 
chain exosite interaction in cleavage of the two factor IX activation bonds. Factor XIa-
CD was severely impaired in its activation of factor IX, demonstrating the importance of 
the heavy chain for both factor IX cleavages. However, unlike other single active site 
species of factor XIa, activation of factor IX by factor XIa-CD resulted in significant 
accumulation of factor IX. This retention of the initial preference for cleavage at the 
Arg145-Ala146 site suggests that Arg180-Val181 may not be readily available for cleavage 
in the zymogen.  This issue will be addressed in Chapter VI.  In addition, the fact that 
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there is a significant accumulation of factor IX during activation by factor XIa-CD 
indicates there is a relatively greater impairment of cleavage of the Arg180-Val181 bond 
compared to the initial cleavage at Arg145-Ala146, indicating that loss of the factor XIa 
heavy chain is more detrimental to cleavage of factor IX. It has recently been reported 
that factor IX activation by factor XIa-CD is non-competitively inhibited by a small 
molecule inhibitor, p-aminobenzamidine (Sinha et al., 2007), suggesting that an exosite 
on the factor XIa catalytic domain may be required for normal recognition of factor IX 
that is less important for recognition of factor IX.  If confirmed, this would offer an 
explanation for the cleavage pattern of factor IX by factor XIa-CD.    
 
Materials and Methods 
Materials— Factor IX, factor IXa,  factor XI, and factor XIa were purchased from 
Hematologic Technologies (Essex Junction, VT). Factor IXa was purchased from 
Enzyme Research (South Bend, IN). In addition, plasma factor XI was prepared as 
described in the Methods section of Chapter IV.  Aprotinin was from Sigma (St. Louis, 
MO). Factor XI deficient plasma was from George King (Overland Park, KS). Methyl-
sulfonyl-D-cyclo-hexyl-glycyl-glycyl-arginine-p-nitroanilide (S-299) from American 
Diagnostics (Greenwich, CT). 1,5-Dansyl-Glu-Gly-Arg-CH2Cl was from Calbiochem (La 
Jolla). 
 
Factor IX activation by factor XIa followed by chromogenic substrate cleavage— 
Factor IX (25–2000 nM) in assay buffer (50 mM hepes pH 7.4, 125 mM NaCl, 5 mM 
CaCl2, 1 mg/ml polyethylene glycol 8000) was activated by factor XIa (1–6 nM active 
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sites), 1/2-factor XIa (1–4 nM active sites), or factor XIa-1/2i (2.5–10 nM active sites) at 
24°C. At various time points between 0 and 120 min, 60-μl aliquots were removed and 
mixed with 6 μl of assay buffer containing 150 μM aprotinin. Aprotinin completely 
inhibited factor XIa without affecting factor IXa activity. Sixty-six microliters of 1 mM 
S299 in assay buffer with 66% ethylene glycol was added to the quenched sample, and 
substrate hydrolysis was followed by measuring the change in absorbance at 405 nm. 
Generation of factor IXa as a function of time was determined by interpolation of the 
linear dependence of the initial rate of S299 hydrolysis on known concentrations of factor 
IXa. Initial rates for progress curves of factor IXa generation were obtained by 
analyzing the first 5 min of each curve with a second order polynomial equation. 
Resulting vo values were fit by the Michaelis-Menten equation, and values for Km and 
kcat were obtained from direct non-linear least squares analysis. The initial 5 min of 
factor IX activation are minimally influenced by product inhibition, and defined the Km 
and kcat values adequately. The values for Km and kcat were used to analyze complete 
progress curves by the integrated Michaelis-Menten equation. With values for Km and 
kcat fixed, full progress curves were fitted simultaneously by the integrated rate equation 
with product inhibition to obtain estimates of Ki for factor IXa. SCIENTIST Software 
was used to analyze the data (MicoMath Scientific Software. Salt Lake City, UT).  
Parameter errors represent 95% confidence intervals. 
 
Activity of factor XIa in plasma clotting assays— Factor XIa proteases were diluted to 
5 g/ml in 20 mM  Tris-Cl, 100 mM NaCl, 1 mg/ml BSA, pH 7.4 and serial 1:2 dilutions 
were prepared in the same buffer. Sixty l of each dilution was mixed with an equal 
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volume of  factor XI deficient plasma, and rabbit brain cephalin, followed by incubation 
for 30 s at 37 oC.  Sixty l of 25 mM CaCl2 was added and the time to clot formation was 
determined on a Dataclot 2 fibrometer (Helena Laboratories, Beaumont, TX). Clotting 
times were plotted against enzyme concentration on a log-log plot, and factor XIa activity 
was determined as a percent of control by comparison to a control curve constructed with 
plasma factor XIa.   
 
Factor IX activation followed by western blotting— Plasma factor IX (100 nM) was 
incubated in assay buffer at 24 °C with various factor XIa species, or with factor VIIa in 
the presence of saturating human tissue factor (Innovin, Dade-Behring, Miami, FL). In 
some reactions, factor XIa inhibited by a tripeptide chloromethyl-ketone (factor XIai) 
was included. At various times, 7 μl samples were mixed with 7 μl of reducing sample 
buffer (233 mM Tris-Cl, 138 mM SDS, 19% glycerol, 10% 2-mercaptoethanol, 0.01% 
bromphenol blue, pH 6.8), fractionated on 12% SDS-polyacrylamide gels, and then 
transferred to nitrocellulose. The primary antibody was goat anti-human factor IX 
polyclonal IgG (Enzyme Research Laboratories, South Bend, IN), and the secondary 
antibody was horseradish peroxidase-conjugated anti-goat IgG. Detection was by 
chemiluminescence. The relative positions of bands representing factor IX, factor IX, 
factor IXa, and factor IXa were determined by western blots of standards for each 
protein. 
 
Titrations of factor XIa by factor IX and factor IXa— Factor XIa (6.25 μM) was 
diluted in titration buffer (50 mM Hepes, 125 mM CaCl2, 1 mg/ml polyethylene glycol 
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8000, pH 7.4) and inhibited with a 10-fold molar excess of 1,5-dansyl-Glu-Gly-Arg-
CH2Cl at 24 °C. Residual factor XIa activity was determined by diluting aliquots to 20 
nM factor XIa in 120 μl of titration buffer with 500 μM S-2366, and monitoring changes 
in absorbance at 405 nm until factor XIa activity was reduced >99.9%. The concentration 
of inhibited active sites per mol of factor XIa was determined by measuring dansyl 
concentration by absorbance at 335 nm with  of 8,000 M-1 cm-1, and factor XIa 
concentration by absorbance at 280 nm (corrected for absorbance of the fluorophore) 
with  of 214,400 M-1 cm-1. Probe incorporation was 1.98 moles per mole of factor XIa. 
Fluorescence titrations were performed with an SLM 8100 fluorometer, using acrylic 
cuvettes coated with polyethylene glycol 20,000. Fluorescence intensity titrations of 
dansyl labeled factor XIa were performed with 335 nm excitation (16 nm band pass) and 
552 nm emission (16 nm band pass) in titration buffer supplemented with 2 μM D-Phe-
Pro-Arg-CH2Cl at 24 °C. The quadratic binding equation was fit to fluorescence changes 
((Fobs - Fo)/Fo = F/Fo) as a function of total factor IX concentration, to determine the 
maximum change in fluorescence (Fmax/Fo), dissociation constant (Kd), and 
stoichiometry (n) using SCIENTIST Software. Parameter errors represent 95% 
confidence intervals. 
 
Preparation of recombinant factor XIa catalytic domain (factor XIa-CD)— 
Recombinant factor XI with Cys362 and Cys482 changed to Ser (factor XI-Ser362,482) 
(Ogawa et al., 2005; Smith et al., 2008), was expressed in HEK293 cells as described as 
described in Chapter IV. Protein from stably transfected clones was purified from 
conditioned media (Cellgro Complete, Mediatech, Herndon, VA) by chromatography 
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using anti-human factor XI-IgG 1G5.12 (Sun et al., 1999). The column was eluted with 2 
M sodium thiocyanate in 25 mM Tris-HCl, pH 7.5, 100 mM NaCl (Tris/NaCl). Protein-
containing fractions were pooled and concentrated by ultrafiltration, dialyzed against 
Tris/NaCl, and stored at  -80 °C. Factor XI-Ser362,482 (100–300 μg/ml) were activated by 
incubation with 2 μg/ml factor XIIa at 37 °C. Complete activation was confirmed by 
reducing SDS-polyacrylamide gel electrophoresis. Factor XIa-Ser362,482, which lacks the 
disulfide bond that connects the factor XIa heavy chain to the catalytic domain, was 
reapplied to the 1G5.12 column. The catalytic domain (factor XIa-CD) binds to the 
column, whereas the heavy chain is found in the flow through. Factor XIa-CD was eluted 
as described above and dialyzed against Tris/NaCl. 
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CHAPTER VI 
 
 
FACTOR XIa EXOSITES AND CLEAVAGE OF FACTOR IX 
 
 
Introduction 
 Most of the work described in this chapter is unpublished and will serve as the 
basis of a manuscript that is currently in preparation. The studies follow-up on the 
observations discussed in Chapter V that the mechanism of factor IX activation by factor 
XIa involves sequential cleavage of factor IX at the Arg145-Ala146 and Arg180-Val181 
bonds with formation of the intermediate factor IX. Published results indicate that an 
exosite interaction involving the factor XIa non-catalytic heavy chain is required for this 
process (Ogawa et al., 2005; Smith et al., 2008).  Work with recombinant factor XI 
chimeras (Sun and Gailani, 1996) and site-directed mutants (Sun et al., 1999) indicate 
that  the  factor XIa A3 domain is required for normal factor IX activation (Figure VI-1),  
 
Figure VI-1. Putative factor IX binding site on the factor XIa A3 domain. (A) Residues 183-
191 are conserved in the A3 domain of factor XI in mammals, but not in PK or the factor XI/PK 
precursor found in other vertebrates. (B) Diagram of human factor XI A3. Residues identified as 
critical for the interaction with factor IX are in blue. (C) In the crystal structure of factor XI, the 
putative factor IX binding site on the A3 domain (green) is buried in an interface with the 
catalytic domain (gray). Arg184 on A3 forms a salt bridge with Asp488 and a hydrogen bond 
with Asn566 on the catalytic domain. In the crystal structure of the isolated factor XIa catalytic 
domain, D488 and N566 interact with other catalytic domain residues, indicating conformational 
changes that occur with protease activation may free residues 183-191, allowing factor IX to 
bind. The factor XI numbering system is used in this diagram. 
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and may contain the proposed exosite. It also appears likely that the C-terminal portion of 
the factor IX Gla domain is required, as discussed in Chapter II (Aktimur, 2003). In this 
chapter, we will present results from experiments designed to examine the importance of 
the factor XIa A3 domain and the factor IX Gla domain to normal activation of factor IX; 
activation without accumulation of an activation intermediate.  The results indicate that 
both the factor XIa A3 domain and the factor IX Gla domain are necessary for the 
observed pattern of factor IX activation. 
 Figure VI-2 shows a schematic diagram of the possible reactions involved in 
converting factor IX to factor IXa. As factor XIa appears to cleave factor IX initially at 
the Arg145-Ala146 bond (Reaction 1) to form factor IX, the lack of accumulation of this 
intermediate strongly suggests that the second cleavage at Arg180-Val181 (Reaction 2) 
must be at least as fast, or perhaps substantially faster than Reaction 1.  Here we describe 
experiments comparing the relative rates of cleavage of Arg145-Ala146 (Reaction 1) and 
Arg180-Val181 (Reaction 3) in factor IX with cleavage of the same bonds in the activation 
intermediates factor IX (Reaction 2) and factor IXa (Reaction 4). The results indicate 
that cleavage of Arg180-Val181 (Reaction 3) is substantially slower in factor IX compared 
to factor IX (Reaction 2), implying that cleavage at Arg145-Ala146 (Reaction 1) 
facilitates cleavage at Arg180-Val181 (Reaction 2).  
 
The Importance of the Factor XIa A3 Domain to Factor IX Activation 
 We determined the importance of the factor XIa A3 domain to factor IX 
intermediate formation by replacing the factor XI A3 domain with the equivalent domain 
from PK.  Recall that PK activates factor IX poorly (Sun  and  Gailani, 1996).  Previously 
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Figure VI-2. Pathways involved in factor IX activation to factor IXa. Factor IX is 
converted to factor IXa by cleavage of the Arg145-Ala146 and Arg180-Val181 bonds, releasing 
the activation peptide (green ribbon).  Conversion of inactive catalytic domain (red circle) to 
active protease (green three-quarter circle) requires cleavage at Arg180-Val181. During 
activation by factor VIIa/TF, factor IX is cleaved at Arg145-Ala146 forming factor IX 
(Reaction 1). Factor IX is subsequently cleaved at the Arg180-Val181 bond (Reaction 2) to 
form factor IXa. Initial cleavage of factor IX at Arg180-Val181 (Reaction 3) is a minor 
reaction.  The product of Reaction 3, factor IXa is converted to factor IXa by cleavage of the 
Arg145-Ala146 bond (Reaction 4). Activation of factor IX by factor XIa, appears to follow the 
same pathways as for activation by factor VIIa/TF (i.e. through Reactions 1 and 2).  
 
we showed that this chimera, factor XIa/PKA3 cleaves the chromogenic substrate S-2366 
in a similar manner to factor XIa, but is a poor activator of factor IX. When reducing 
western blots of factor IX activated by recombinant wild type factor XIa (factor XIaWT) 
or factor XIa/PKA3 are compared (Figure VI-3A and 3B) two important differences are 
apparent. First, the rate of cleavage of zymogen factor IX is slower with factor 
XIa/PKA3, consistent with our published kinetics data (Sun and Gailani, 1996). Second, 
there is a pronounced accumulation of factor IX during the reaction with the chimera. 
Little if any factor IXa is observed (very little heavy chain noted on the blot). In fact, 
the results are similar to those shown in Chapter V for factor IX activation by factor XIai 
in   the   presence  of  factor  XIai  (Figure V-5)  and  for  the isolated factor XIa catalytic  
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Figure VI-3. Factor IX activation by factor XIa - Importance of the A3 domain. Shown are 
reducing western blots of time courses of factor IX (100 nM) activation by (A) factor XIa - 2 nM, 
(B) factor XIa/PKA3 - 5 nM, (C) factor XIa 2 nM in the presence of 50 nM antibody O1A6, (D) 
factor XIa-CD 5 nM (E) factor XIa/PKA3 - 5 nM, and (F) a chimera consisting of the 
prekallikrein heavy chain and the factor XIa catalytic domain (PK-HC/FXIa-CD) - 5 nM. All 
values are active site concentrations. Note that the time courses differ between panels. Migration 
of protein standards is shown for zymogen factor IX (FIX), the large fragment of factor IX 
(FIX), the heavy chain of factor IXa (HC), and the light chain of factor IXa or factor IX 
(LC). 
 
domain (Figure V-6). The result, in conjunction with our previous observation that factor 
IX activation by factor XIa/PKA3 is characterized by a >30-fold increase in Km (Sun and 
Gailani, 1996), are consistent with the factor XIa A3 domain containing an important 
exosite for factor IX activation. Similarly, factor IX was seen to accumulate slowly 
when factor IX was activated by factor XIa in the presence of a monoclonal anti-factor 
XI IgG (O1A6 - Figure VI-4) (Tucker et al., 2009). O1A6 is an antibody that binds to 
the factor XIa A3 domain (Figure VI-4A) at residues that overlap or are in close 
proximity to the factor IX binding site (compare Figure VI-4B and C). In this reaction, 
activation is considerably slower than with factor XIa/PKA3, probably because of steric 
interference caused by the antibody (Figure VI-3C).  
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Figure VI-4. Monoclonal anti-human factor XI IgG O1A6. (A) Chemiluminescent western 
blot of non-reducing SDS-PAGE using O1A6 as the detection antibody.  The proteins on the 
blot are: H - human factor XI; A1, A2, A3, or A4 - human factor XI with the indicated 
prekallikrein apple domains; PK - human PK. Note that factor XI/PKa4 is a monomer. (B and C) 
Schematic diagrams of the A3 domain of human factor XI showing the positions of (B) amino 
acids that are required for factor IX binding (in green) and (C) amino acids that may be part of 
the binding site for the O1A6 antibody (in red). Data in panels B and C were obtained using a 
panel of alanine mutants of factor XI (Sun et al., 1991). 
 
 
 We also compared activation of factor IX by factor XIa/PKA3 directly to factor 
XIa-CD and a chimera consisting of the entire PK heavy chain (all four apple domains) 
and the factor XIa catalytic domain (PK-HC/FXIa-CD) (Figure VI-3D-F) (Cheng et al., 
2003). For these reactions, which involved substantially longer time courses than those in 
Figure VI-3A-C, the rate of disappearance of zymogen factor IX is similar, although 
considerably slower than with factor XIa-WT (Figure VI-3A). However, factor IXa is 
observed in the reaction with factor XIa-CD, but not in reactions with factor XIa/PKA3 
or PK-HC/FXIa-CD. First, the similarity in reactions with factor XIa/PKA3 and PK-
HC/FXIa-CD support the conclusion that most of the binding energy for the factor XIa-
factor IX interaction is within the A3 domain, and other apple domains probably do not 
directly contribute.  Once the A3 domain is replaced with a domain that does not bind 
factor IX, it may actually cause steric interference that prevents the catalytic domain from 
making the second cleavage at Arg180-Val181, as factor XIa-CD is able to do. 
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The Importance of the Factor IX Gla Domain to Activation by Factor XIa 
 The factor IX Gla domain may serve as a recognition site for factor XIa, as 
replacement of the Gla with factor VIIa Gla results in a molecule (factor IX/VII-Gla) that 
binds poorly to factor XIa and, probably as a consequence, is activated poorly by factor 
XIa (Aktimur et al., 2003). The importance of the Gla domain interaction may be why 
factor IX activation by factor XIa is Ca2+ dependent, as other reactions involving factor 
XI/XIa do not require Ca2+. It is important to note that factor IX/VII-Gla is activated 
normally by factor VIIa/TF (Aktimur et al., 2003), indicating that the Gla substitution 
does not interfere with phospholipid binding or protein-protein interactions with factor 
VIIa/TF.  This implies that factor VIIa and factor XIa bind to distinct sites on factor IX. 
 We conducted experiments to determine if conditions that affect the Gla domain 
influence the cleavage pattern generated when factor IX is activated by factor XIa. First, 
we examined activation in the presence of the Ca2+ chelator EDTA (Figure VI-5A). As 
with reactions using factor XIa/PKA3, the reaction in the absence of Ca2+ is 
characterized by significant accumulation of factor IX and a slow generation of factor 
IXa. Factor IX also accumulated when factor IX was activated by factor XIa in the 
presence of a monoclonal antibody (SB 249417, John Toomey, GlaxoSmithKline), which 
is a humanized murine antibody against the human factor IX-Gla domain (Figure VI-5B) 
(Aktimur et al., 2003).  The perturbation in activation is similar to the one caused by 
interfering with the factor XIa A3 domain, raising the possibility that the factor IX Gla 
domain is interacting with the factor XIa A3 domain. This interaction appears to be 
necessary for both factor IX cleavages, but disruption of the interaction causes a 
disproportionate effect on the second cleavage at Arg180-Val181. 
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Figure VI-5. Factor IX activation by 
factor XIa - Importance of the Gla 
domain. Shown are reducing western 
blots of time courses of factor IX (100 
nM) activation by (A) factor XIa - 2 nM 
in the presence of 25 mM EDTA or (B) 
factor XIa - 2 nM in the presence of the 
anti-human factor IX Gla domain 
monoclonal antibody SB 249417. 
Migration of protein standards is shown 
for zymogen factor IX (FIX), the large 
chain of factor IX (FIX), the heavy 
chain of factor IXa (HC), and the light 
chain of factor IXa or factor IX (LC). 
 
Rates of Cleavage of the Arg145-Ala146 and Arg180-Val181 Bonds in Factor IX and Its 
Activation Intermediates 
 
 As discussed, factor IX must be cleaved at two internal bonds for full activation, 
and modeling and crystallographic studies do not provide an obvious reason that initial 
cleavage at either bond would be preferred. If we assume that initial cleavage could occur 
at either the Arg145-Ala146 or the Arg180-Val181 bond in factor IX, then there are four 
half-reactions possible for the conversion of factor IX to factor IXa, as shown in Figure 
VI-2. Factor VIIa/TF and factor XIa both make their initial cleavage in factor IX after 
Arg145, but the mechanistic basis for this is unclear.  Conversion of prothrombin to -
thrombin can also proceed through more than one intermediate, but one pathway is 
favored (Krishnaswamy, 2004; Bock et al., 2007). The mechanistic basis for this involves 
significantly different kcats for cleavage at different sites in the zymogen. Cleavage at the 
preferred site facilitates cleavage at subsequent sites by allowing the substrate to achieve 
a different conformation that presents the cleavage site more efficiently to the active site 
of the enzyme.  Here we present results from experiments designed to compare the rates 
of cleavage of the individual scissile bonds.    
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 In experiments in Chapter V examining factor IX activation, we generated full 
progress curves for factor IX activation using a chromogenic substrate assay, and 
determined initial rates from these curves to establish Km and kcat for activation, and Ki 
for product inhibition (Smith et al., 2008). This technique will not be useful for studying 
factor IX conversion to factor IX, which is not an active protease.  Furthermore, some 
of our studies will require recombinant variants of factor IX lacking an activation 
cleavage site.  Species of recombinant factor IX with an activated catalytic domain 
(factor IXa and factor IXa) do not cleave the chromogenic substrate S299 very well.  
For these reasons, we opted to follow factor IX activation by densitometry of GelCode 
blue stained SDS-polyacryalmide gels imaged at infrared wavelengths.  The low signal-
to-noise ratio with this technique allows us to examine factor IX activation at 
concentrations as low as 10 nM (Figure VI-6). 
 Initial experiments examined conversion of factor IX and factor IXa 
(Reactions 2 and 4 in Figure VI-2) to factor IXa. The intermediates were prepared from 
plasma factor IX   (Figure VI-7A, see Methods).   The Arg180-Val181 bond in factor IX 
 
Figure VI-6. Assessing factor IX activation by infra-red densitometry. The top images are 
derived from infrared images of (A) a time course of factor IX (250 nM) activated by 2 nM 
factor XIa, and (B) a set of protein standards used to determine amounts of factor IX and factor 
IXa on the time course. A standard (ST) is also included in the right hand lane of the time 
course. At the bottom are gray scale images used for densitometry. 
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Figure VI-7. Factor IX activation intermediates prepared from plasma factor IX, and 
recombinant factor IX activation cleavage site mutants. (A) Control (C) mixture of factor IX 
and factor IXa, and purified plasma factor IX and factor IXa. (B) Recombinant factor IX 
(WT), factor XIR145A, and factor XIaR180A. Mass standards (kDa) are at right. (C) Reduced 
partially activated proteins from panel B. Factor IX (WT) is partially activated by factor VIIa/TF 
to product and intermediate. Abbreviations for panels A and C: Z - zymogen factor IX, IX - 
large fragment of factor IX, IXa - large fragment of factor IXa, HC - heavy chain (catalytic 
domain) of factor IXa and factor IXa, LC - light chain of factor IX and factor IXa. 
 
and the Arg145-Ala146 bond in factor IXa were cleaved by factor XIa with similar 
kinetic parameters (Table VI-1), and the values agree with those for overall conversion 
of factor IX to factor IXa determined by the same technique.  Note that the values agree 
with those for factor IX activation by chromogenic substrate assay (Table V-1). The fact 
that the  parameters for  Reaction  2  (Figure VI-2)  are  similar  to  those  for  the overall  
 
Table VI-1. Kinetic parameters for activation of factor IX, factor IX  and factor IXa  by 
factor XIa. Km and kcat for activation were based on initial rates for factor IX activation from full 
progress curves as described under Methods.  The resulting vo values were analyzed by fitting the 
Michaelis-Menten equation, and values for Km and kcat were obtained from direct non-linear least 
squares analysis. Values for Km and kcat were used to analyze the complete progress curves by the 
integrated Michaelis-Menten equation. With values for Km and kcat fixed, full progress curves 
were fitted simultaneously by the integrated rate equation with product inhibition to obtain 
estimates of Ki for factor IXa. Errors in parameters represent 95 % confidence intervals. 
 
Substrate Km (nM) kcat (min-1) Ki (nM) 
Factor IX 82 ± 50 30 ± 6 24 ± 28 
Factor IX 57 ± 48 19 ± 4 20 ± 21 
Factor IXa 108 ± 80 30 (fixed) 22 ± 2  
 115 
activation of factor IX to factor IXa (which proceeds through Reactions 1 and 2) suggest 
that the rates for Reactions 1 and 2 are similar. This interpretation is consistent with the 
fact that Reaction 4 (cleavage at Arg145-Ala146 in factor IXa) has similar kinetic 
parameters to Reaction 2. 
 To definitively demonstrate that conversion of factor IX to factor IX has similar 
kinetic parameters to those for Reactions 2 and 4, we are in the process of examining 
cleavage of recombinant factor IX that can only be cleaved at the Arg145-Ala146 bond 
(factor XIaR180A, Arg180 replaced with alanine - Figure VI-7B and Figure 8). The final 
product of factor XIa of factor IX-Ala180 is factor IX (Figure VI-7C). We also have 
generated recombinant factor IX that can only be cleaved at the Arg180-Val181 bond 
(factor XIR145A), Arg145 replaced with alanine - Figure VI-7B). The final product of 
factor XIa of factor IX-R145A is factor IXa (Figure VI-7C). Comparing the kinetics of 
cleavage of these mutants to their respective products will allow us to test the hypothesis 
that cleavage of the Arg180-Val181 bond in zymogen factor IX (Reaction 3 in Figure VI-
2) is much slower than at Arg145-Ala146 (Reaction 1). These studies are in progress. In 
preliminary work, we have indeed observed that factor XIaR180A is converted to its final 
product at a rate that appears to be much faster than for factor XIR145A (Figure VI-8). 
 
Discussion 
 In this chapter we have presented evidence that factor IX activation by factor XIa 
is influenced by binding interactions with exosites on the heavy chain of factor XIa 
(Ogawa et al., 2005). Specifically, one or more sites on the factor XIa A3 domain appear 
to be involved. Furthermore, the cognate factor IX binding site for this factor XIa  exosite 
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Figure VI-8. Conversion of factor XIR145A to factor IXa  and factor XIaR180A to factor 
IX  by factor XIa. (Top).  The alanine replacement that abolishes each factor IX cleavage site is 
represented by the symbol , at either end of the activation peptide (green ribbon). Cleavage of 
factor IXR145A (left) can only be made after Arg180, producing factor IXa. Cleavage of factor 
IXR180A (right) can only produce factor IX. (Bottom) Recombinant factor XIR145A or factor 
XIaR180A (100 nM) in Assay Buffer were incubated at 24 ˚C with factor XIa (0.2 nM active 
sites). Aliquots were removed at indicated reaction times into denaturing reducing buffer, 
fractionated on 12% polyacrylamide-SDS gels, and analyzed by western blotting as described 
under Methods. Migration of protein standards is shown for zymogen factor IX (Z), the large 
fragment (activation peptide + heavy chain) of factor IX (IX), the large fragment (activation 
peptide + light chain) of factor IXa (IXa), the heavy chain of factor IXa or factor IXa (HC), 
and the light chain of factor IXa or factor IX (LC). 
 
 
appears to be the factor IX Gla domain. Since perturbation of either of these sites results 
in markedly slower factor IX cleavage by factor XIa, the conclusion that these sites are 
required for initial substrate recognition seems reasonable. Interestingly, binding 
interactions mediated by these sites also appear to influence the release of the 
intermediate factor IX from the enzyme/substrate complex. This observation implies 
that the A3-Gla domain interaction is more important for cleavage after Arg180 than for 
cleavage after Arg145, but does not explain why we do not normally observe the 
accumulation of factor IX.  
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 The implication of the study with factor XIai in Chapter V (Figure V-5) is that 
factor IX is released from factor XIa.  Given the lack of intermediate accumulation on 
western blots, we would reason that the initial cleavage of factor IX by factor XIa after 
Arg145 is rate limiting and that the cleavage of factor IX to form factor IXa should be 
significantly faster. However, Wolberg et al. estimated that factor IX and its two possible 
activation intermediates are cleaved by factor XIa at roughly similar rates (Wolberg et 
al., 1997). The preliminary results presented in this chapter concur with this finding.  
Given this, it is somewhat surprising that we do not see some degree of intermediate 
accumulation early in time courses, if factor IX is released from factor XIa and must be 
recaptured. At early points in the time course, factor IX zymogen is present in vast excess 
over factor IX and should compete with the intermediate for binding to factor XIa, as 
factor XIai appears to have done in the experiment in Figure V-5. This assumes, of 
course, that factor IX and factor IX bind with similar affinities and to a similar site (or 
sites) on factor XIa.  We showed that factor IX and factor IXa have similar affinities for 
factor XIa (Figure V-7).  The comparable Kms for cleavage of factor IX and factor IX 
suggest similar affinities for factor XIa for these two proteins as well.  
 The issue of whether or not there are distinct binding sites for factor IX and factor 
IX is an interesting one.  Recently, Sinha et al. raised the possibility of a factor IX 
binding site on the factor XIa catalytic domain (outside of the active site) that was 
primarily involved with the initial interaction with factor IX (Sinha et al., 2007), and 
suggested that the interaction with the factor XIa heavy chain was more important for the 
interaction with factor IX.  This is consistent with our observation that interfering with 
the factor IX interaction with the heavy chain results in factor IX accumulation (Figure 
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VI-3 and 4).  Work done previously in our laboratory showed that factor IX and factor 
IXa binding to factor XIa is mutually exclusive (Ogawa et al., 2005), indicating that 
zymogen and product bind to the same sites on factor XIa.  Work is currently underway 
to determine whether factor IX and factor IX compete for binding sites on factor XIa.  
 None of the preceding observations provide a mechanistic explanation for the 
preferential cleavage of factor IX at the Arg145 bond by both factor XIa and factor 
VIIa/TF. Experiments in which the purified intermediates factor IX and factor IXa 
were activated by factor XIa only address questions of how factor XIa processes these 
proteins, which do not normally accumulate. The cleavage site mutants factor IXR145A 
and factor IXR180A were constructed to address the issue of how factor XIa processes 
zymogen factor IX. The comparatively slow activation of factor IXR145A by factor XIa 
(Figure VI-8) suggests that the factor XIa active site cannot properly access the Arg180-
Val181 bond in that molecule. It is reasonable to conclude that a decrease in kcat, rather 
than an increase in Km, is responsible for this observation, since both cleavage site 
mutants are zymogens and should bind equally well to factor XIa. We are currently using 
the densitometry techniques described in this chapter to determine the rate constants for 
conversion of the cleavage site mutants to their respective products.  
 The conversion of prothrombin to -thrombin has been extensively studied 
(Krishnaswamy, 2004; Bock et al., 2007), and is the most appropriate model from which 
to consider exosite-mediated mechanisms involved in activation of factor IX. As with 
factor IX activation, prothrombin must be cleaved at two bonds (Arg271-Thr272 and 
Arg320-Ile321) to generate the final product. Cleavage at the Arg320-Ile321 bond is 
favored because of a 30-fold faster kcat, resulting in formation of the intermediate 
 119 
meizothrombin.  Subsequent cleavage at Arg271-Thr272 in meizothrombin is kinetically 
favorable relative to cleavage of the same bond in zymogen prothrombin.  Despite these 
similarities with factor IX activation by factor XIa, there appear to be two notable 
differences between the processes.  First, meizothrombin is observed to accumulate to 
various degrees (depending on the experiment) during prothrombin activation, consistent 
with the intermediate being released from the prothrombinase complex.  Second, in the 
absence of the cofactor factor Va, prothrombin is preferentially cleaved not at the Arg320-
Ile321 bond, but at the Arg271-Thr272 bond to form the intermediate prethrombin 2 - F1.2 
complex.  This suggests that exosites not only determine order of cleavage of the bonds 
in prothrombin and, but also which bonds are accessible to the protease.  In contrast, 
factor IX activation by factor XIa or factor VIIa/TF appears to always proceed through 
factor IX, suggesting that the second bond is not normally accessible.  Thus, it may be 
difficult to extrapolate from the lessons learned from prothrombin activation to 
completely explain activation of factor IX by factor XIa.  
 At this point, we should mention that we have observed cleavage of the Arg180-
Val181 bond by factor XIa in zymogen factor IX, but only in two situations, and under 
highly unusual conditions. When recombinant factor IX is expressed in the presence of 
the vitamin K antagonist warfarin to block -carboxylation, the resulting protein is 
cleaved poorly by factor XIa, and cleavage is preferentially at the Arg180-Val181 bond 
(data not shown).  This is difficult to explain purely by a poor interaction between Gla 
domain and factor XIa A3, as it differs from results for reactions run in the presence of 
EDTA or the anti-Gla domain antibody SB 249417 (Figures VI-5), and may indicate 
significant distortion of factor IX resulting in an unusual interaction with the protease. A 
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naturally occurring factor XI mutation in the catalytic domain associated with a 
dysfunctional circulating factor XI variant (factor XIa with Thr 575 replaced with Met - 
T213M in chymotrypsinogen) was recently reported (Mitchell et al., 2007). We 
expressed this protein and noted that it cleaved factor IX relatively slowly, with 
simultaneous generation of both intermediates (Figure VI-9). The methionine 
substitution in the mutant almost certainly causes significant perturbations in the enzyme 
active site, changing the nature of the protease. These peculiar findings indicate that the 
Arg180-Val181 is exposed to some extent on the surface of factor IX, but is not readily 
accessible to factor XIa in the normal zymogen.  
 
Figure VI-9. Activation of factor IX by 
factor XIaT213M. Western blot (12% 
polyacrylamide reducing gel) of factor IX 
(100 nM) incubated with factor XIaT213M 
(5 nM). Note that bands corresponding to 
both possible activation intermediates are 
present. Migration of protein standards is 
shown for zymogen factor IX (IX), the 
large fragment of factor IX (IX), the 
large fragment of factor IXa (IXa), the 
catalytic domain of factor IXa or factor 
IXa (CD), and the light chain of factor 
IXa or factor IX (LC). 
 
 
Methods 
Infrared imaging-densitometry of protein on polyacrylamide gels. SDS-
polyacrylamide gels are stained with GelCode blue (Pierce). Conversion of factor IX or 
factor IX to factor IXa is studied with non-reducing gels (factor IXa is ~10 kDa 
smaller than factor IX and factor IX), while factor IX conversion to factor IX and 
factor IXa is studied with reducing gels. Gels are destained in water for 24 hours, and 
particulate matter is removed by gently wiping the surface with dishwashing liquid 
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(Palmolive). Infrared imaging (excitation  685 nm, emission  720 nm) is done on an 
Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE). The instrument 
software converts infrared data to grayscale images for densitometry. To determine 
amounts of protein per lane, standards are run on a separate gel, with one standard on the 
time course gel. Full progress curves are plotted from the data. 
 
Recombinant factor IX. cDNAs for factor IX, factor IX-Ala145 and factor IX-Ala180 are 
expressed in HEK293 cells (ATCC CRL1573) in Cellgro Complete serum free medium 
(Mediatech, Herdon, VA) supplemented with 10 μg/ml vitamin K and 10 μg/ml soy bean 
trypsin inhibitor (Aktimur et al., 2003). A high percentage of vitamin-K dependent 
protein produced in this line is properly -carboxylated (Yan et al., 1990; Wong et al., 
1999; Yan 1996) Factor IX is purified from media by affinity chromatography with an 
antibody to the -carboxylated Gla domain (SB 249417).  
 
Preparation of factor IX and factor IXa  from plasma factor IX. To prepared 
factor IX, factor IX (3-4 μM) is incubated with 150 nM factor XIa-Pro192 in TBS, pH 
7.4, containing 0.1% PEG, 5 mM CaCl2 at 37 
oC for 24 h. Traces of factor IXa are 
inhibited by incubation at 4 oC with a 20-fold molar excess of biotinylated EGR-CMK, 
followed by 1 h at RT with streptavidin immobilized on agarose. The supernatant 
contains pure factor IX. To prepare, factor IXa, factor IX (3-4 μM) is incubated with 
150 nM Russell Viper Venom protease in TBS, 0.1% PEG, 5 mM CaCl2 pH 7.40 at 37 
oC 
for 30 min. The mixture is passed over a 5 mL HiTrap Heparin FPLC column in 20 mM 
citric acid pH 7.40. Protein is eluted with a 0 to 1 M NaCl gradient (Bajaj et al., 1983). 
Fractions containing pure factor IXa by SDS-PAGE are dialyzed against TBS, pH 7.4. 
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Preparation of recombinant factor XI and factor XI/PK chimeras. Factor XI and 
factor XI/PK chimeras are expressed in HEK293 cells under the same culture conditions 
for factor IX expression, but without vitamin K (Sun et al., 1999). Protein is purified 
from conditioned media by chromatography on anti-human factor XI-IgG 1G5.12. Factor 
XI (300 μg/ml) is converted to factor XIa by incubation in TBS with factor XIIa (2 
μg/ml) at 37 °C. Complete conversion to factor XIa is confirmed by reducing SDS-
PAGE.  Factor XIIa is removed by reapplication to the 1G5.12 antibody column.  
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CHAPTER VII 
 
MODELS FOR FACTOR IX ACTIVATION BY FACTOR XIa 
  
 Exosites on coagulation proteases are critical for determining substrate specificity 
and order of bond cleavage. We have shown that this principle applies to activation of 
factor IX by factor XIa. Specifically, factor XIa (1) requires only a single active subunit 
to activate factor IX, (2) cleaves factor IX initially at the Arg145-Ala146 bond, and (3) 
has at least one exosite (A3) required for factor IX activation. The simplest way to treat 
the reaction, involves postulating a single factor XIa exosite on the A3 domain that would 
bind  factor  IX  and  its activation intermediates (Figure VII-1). Here, factor IX engages 
 
Figure VII-1. Factor IX activation by factor XIa involving a single exosite and release of 
intermediate. The factor XI apple domains are shown as four circles. A1, A2, and A4 are in 
white, and A3 with the factor IX binding exosite is in blue . The factor XIa catalytic domain is 
a green ellipse with the active site indicated by . The factor IX catalytic heavy chain (dark blue 
ellipse) and light chain (yellow ellipse) are connected by a line representing a disulfide bond. The 
activation peptide is the gray oval. Bi-directional arrows represent reversible binding, and 
directional arrows are activation cleavages. Factor IX is activated by a single factor XIa subunit 
by sequential cleavage after Arg145 and Arg180, with the intermediate factor IX released from 
the protease. Factor IX interacts with a single exosite on the A3 domain of factor XIa.  
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the exosite, followed by a docking interaction at the active site and catalysis of the 
Arg145-Ala146 to form factor IX.  The intermediate is released from the protease, and 
must rebind to be cleaved at the Arg180-Val181 bond to form factor IXa. A potential 
problem with this model is that it seems to require the second cleavage at Arg180-Val181 
to be more rapid than the initial cleavage; something we have not been able to 
demonstrate. Also, the more deleterious effect of disrupting the A3 exosite interaction on 
the Arg180-Val181 cleavage suggests the process may be more complex. 
 The model in Figure VII-2 is similar to the one in Figure VII-1, except that two 
factor IX binding exosites are proposed, one on the catalytic domain (Sinha et al., 2007) 
and one on A3.  We hypothesize that both exosites are required for the initial cleavage at 
Arg145-Ala146,  but  only  A3 is  required for cleavage of factor IX at the Arg180-Val181  
 
Figure VII-2. Factor IX activation by factor XIa involving two exosites and release of 
intermediate. See the Figure VII-1 figure legend for details regarding this schematic diagram.  In 
the reaction shown here, a second factor IX-binding exosite on the catalytic domain  is 
involved. Factor IX is activated by ordered sequential cleavage of its two bonds by a factor XIa 
subunit, with involvement of two exosites in initial factor IX binding.  This also involves release 
of factor IX, which rebinds to the protease A3 domain prior to conversion to factor IXa. 
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bond. The second model may offer a better explanation as to why factor IX accumulates 
when the interaction with the A3 exosite is disturbed. While much of our data are 
consistent with either models, both of which involve release of an intermediate, the 
similar rates of cleavage of the two bonds suggests that we should see some accumulation 
of factor IX, at least early in time courses. Another factor to consider is that while 
including factor XIai in factor IX activation reactions results in factor IX accumulation, 
a large excess of factor XIai (1000-fold) is required to see any intermediate accumulation. 
 The model in Figure VII-3 is most compatible with all available information.   It 
shows  a  type of processive mechanism (Breyer and Matthews, 2001). That is, it involves  
 
Figure VII-3. A model for factor IX activation by factor XIa that does not involve release of 
an intermediate (processive mechanism). See the Figure VII-1 figure legend for details 
regarding this schematic diagram.  In the reaction shown here, a second factor IX-binding exosite 
on the catalytic domain  is involved. Factor IX is activated by sequential cleavage of its two 
bonds by a single factor XIa subunit. Note that factor IX does not dissociate from factor XIa 
after cleavage at the Arg145-Ala146 bond, but is transferred from the exosite on the catalytic 
domain to the exosite on A3, which mediates the second cleavage. The unidirectional arrow with 
the red question mark indicates that we are uncertain if this step is reversible. We postulate that 
such a mechanism could explain why very high concentrations of factor XIai (Figure V-5) are 
required to induce factor IX accumulation during activation. 
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sequential cleavage of the two factor IX bonds but does not involve release of an 
intermediate. An example of an enzyme relevant to blood coagulation that operates 
through a processive mechanisms is the vitamin K-dependent -glutamyl carboxylase that 
modifies the Gla domains of prothrombin and factors VII, IX and X (Berkner, 2008). 
Each protein requires the modification of 10-13 glutamic acid residues, and the enzyme 
accomplishes this prior to releasing the final product.  In the case of factor IX activation 
by factor XIa, we propose that an exosite on the catalytic domain is necessary for initial 
interaction with the substrate.  After cleavage of Arg145-Ala146 to form factor IX, a 
conformational change in the substrate allows interaction with the exosite on the A3 
domain, which facilitates cleavage at Arg180-Val181 to form factor IXa.   
 This scheme offers an explanation for the lack of intermediate accumulation 
during time courses of factor IX activation that is not dependent on rapid cleavage of the 
Arg180-Val181 bond, as in the models in Figures VII-1 and VII-2. At first glance, this 
model may not seem to be compatible with the observation that factor IX accumulates 
in the presence of factor XIai (Figure V-5), which suggests that factor IX has been 
released from the protease.  We propose an alternative interpretation. Factor XIai, in 
sufficient concentration, may interfere with the transfer between exosites, giving the 
impression that factor IX has been released from the protease. We did not see 
intermediate accumulation at 500-fold excess factor XIai over factor XIa, even though 
the rate of the overall reaction was decreased. Intermediate accumulation required at least 
a 1000-fold molar excess of factor XIai. If transfer of factor IX from one exosite to the 
other on factor XIa does not normally result in a free intermediate, then it may require 
very high concentrations of factor XIai A3 domains to "capture" the intermediate as it 
 128 
transits from one exosite to the other.  Experiments to clearly establish the presence of a 
factor IX binding exosite on the factor XIa catalytic domain are currently underway in 
our laboratory. We are also working to determine if factor IX and factor IX bind to 
similar sites on factor XIa. This information will facilitate work to establish the validity 
of the models proposed here. 
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CHAPTER VIII 
 
SUMMARY OF THE THESIS AND FUTURE DIRECTIONS 
 
 After its initial discovery in the mid-1950's, there was considerable interest in 
factor XIa because of its interaction with the important coagulation protein, factor IX.  
Indeed, congenital factor XI deficiency was known at one time as hemophilia C (Gailani 
and Neff, 2009a). Enthusiasm waned as it became clear that the bleeding disorder 
associated with factor XI deficiency was far less severe than in hemophilia B (factor IX 
deficiency).  It now appears that factor XIa plays a relatively minor role in hemostasis 
(normal clot formation at a site of vascular injury) in most situations. By extrapolation, it 
was assumed that this protease did not contribute significantly to thromboembolic 
disease. However, recent work with vascular injury models in animals suggests that 
factor XIa plays a disproportionately greater role in thrombosis (Gailani and Renné, 
2007a, 2007b), the production of a pathologic clot that occludes a blood vessel, than it 
does in hemostasis. These results are consistent with epidemiologic data from human 
populations showing that elevated factor XI levels are a risk factor for both arterial 
(Doggen et al., 2006) and venous (Meijers et al., 2000) thrombosis.  These observations 
have stimulated interest in designing novel pharmaceutical agents that target factor XIa, 
or some aspect of factor XIa-mediated factor IX activation (Gailani et al., 2009b).  
 Activation of factor IX by factor XIa has features that distinguish it from the 
biochemical reactions involving the vitamin K-dependent coagulation proteases. For 
example, factor XIa does not require phospholipid or cofactors for maximum catalytic 
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efficiency. These features, combined with the highly unusual structure of factor XI, make 
it difficult to predict the mechanism for this reaction based on the body of knowledge 
available for other coagulation protease reactions. It was our goal to study the mechanism 
by which factor IX is activated by factor XIa, to facilitate efforts to develop therapeutics 
that target this reaction. The work has lead to several novel observations concerning 
factor XIa and its mechanism of action.   
 First, we identified a form of factor XIa with only a single activated subunit.  
While the existence of this species, which we named 1/2-factor XIa, was predicted over 
thirty years ago (Bouma and Griffin, 1977), we are the first to identify, purify and 
characterize it. Furthermore, we observed 1/2-factor XIa formation in plasma, raising the 
distinct likelihood that this protease is a physiologically, or pathologically, relevant 
molecule. Given the difficulty in producing fully activated factor XIa in vitro, it is 
reasonable to conclude that 1/2-factor XIa may be the predominant species formed in 
plasma during coagulation. If subsequent work bears this out, it is likely that the entire 
body of work related to factor XIa may need to be reconsidered, as it is based exclusively 
on studies with fully activated protease. 
 The availability of 1/2-factor XIa and related single active site species provided us 
with unique tools to address another conundrum regarding factor XIa biology - its 
capacity to activate factor IX without intermediate accumulation. The prevailing opinion 
was that the dimeric structure of factor XIa was key to its ability to do this, but we 
showed that the capacity to activate factor IX is contained within a single factor XIa 
subunit. This, of necessity, implies sequential cleavage of the two scissile bonds in factor 
IX. We are the first to clearly show that initial cleavage is at the Arg145-Ala146 bonds. 
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 The combination of sequential cleavage of the factor IX scissile bonds and the 
absence of intermediate accumulation could be explained by either of two mechanisms.  
Initially we thought that the most likely scenario was that the intermediate, factor IX, 
would be released form factor XIa, and would need to re-bind to factor XIa to complete 
activation. In this case, the second cleavage at Arg180-Val181 would have to be 
considerably more rapid than the cleavage at Arg145-Ala146 to account for the lack of 
intermediate accumulation.  To our surprise, the rates of cleavage of the two bonds were 
similar.  This, along with the data indicating that factor XIa may have more than one 
exosite for substrate binding (Sinha et al., 2007) led us to postulate a processive 
mechanism where factor IX is processed to the final product, factor IXa, without 
intermediate release. 
 Most processive enzymes are large multi-subunit proteins, with substrates passed 
from one subunit to another (Breyer and Matthews, 2001). The substrates of processive 
enzymes also often have repetitive structures. DNA polymerase is a classic example of a 
multi-unit processive enzyme that catalyzes multiple reactions without dissociating from 
its substrate. In this regard, factor XIa is considerably smaller and simpler than most 
processive enzymes. A substantial amount of work remains to be done to definitively 
establish the mechanism by which factor XIa cleaves factor IX without intermediate 
accumulation. This continues to be a major area of emphasis in our laboratory. 
 Having demonstrated that factor XIa does not need to be a dimer in order to 
activated its substrate, the question of why the protease is dimeric remains open. Our 
working hypothesis is that 1/2-factor XIa is a hybrid molecule with different properties 
than either factor XI or factor XIa. For example, factor XI can bind to the platelet 
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receptor GP1b (Walsh, 2004) in an interaction involving the A3 domain, while factor 
XIa does not bind to this receptor (Sinha et al., 1984; Walsh, 2004).  As discussed, factor 
IX binds to factor XIa, but not factor XI.  Hypothetically, 1/2-factor XIa could bind to 
GP1b through its inactive subunit, while catalyzing conversion of factor IX to factor 
IXa - something that neither factor XI nor factor XIa would be able to do. We think that 
this chimeric ability is important for 1/2-factor XIa activity in vivo, where the protease 
would need to anchor to platelets at a wound site so as not to be swept away by the 
flowing blood. Indeed, recent work (Tucker et al., 2009) indicates that platelets are 
required for factor XIa to contribute to fibrin formation under flow conditions in vitro. 
The dimeric structure of factor XI/XIa, therefore, may be an alternative strategy to having 
a Gla domain to allow a protein to bind to surfaces during hemostasis. Work in our 
laboratory is currently addressing the importance of the dimeric structure of factor XI to 
thrombus formation in animal models.  
 Current drug design efforts for anti-thrombotic agents that target factor XIa are 
focused on developing small molecule inhibitors that block the protease active site. This 
is a standard approach when trying to therapeutically inhibit an enzyme. Because the 
catalytic active sites of trypsin-like protease share features in common, inhibitors 
designed to target one protease will often cross-react with other members of the trypsin 
family, producing undesirable effects. Targeting protease exosites, which hypothetically 
would be a way to specifically limit a single protease-substrate interaction. has received 
comparatively less attention, but is gaining in popularity.  The drug Xigris (recombinant 
activated protein C) has beneficial anti-inflammatory properties when used as a treatment 
during sepsis in humans, but has the undesirable side effect of causing excessive bleeding 
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because of its ability to degrade factors VIIIa and Va (Levi, 2008). Work is underway to 
modify exosites on this molecule so that it no longer engages these key coagulation 
factors (Griffin et al. 2007). Similarly, -thrombin has been converted to an anti-
coagulant molecule by modifications that cause it to lose its procoagulant properties, but 
retain its ability to activate the anticoagulant protease protein C (Gruber et al., 2007). Our 
work suggests that the principle of exosite blockade/modification could apply to factor 
XI/XIa. The antibody O1A6 (discussed in chapter VI) appears to specifically interfere 
with factor IX binding to factor XIa. This antibody was recently shown to be an 
effective anti-coagulant in a baboon arterio-venous shunt thrombosis model (Tucker et al. 
2009). We are currently evaluating other antibodies targeting various parts of factor XIa 
outside the catalytic domain for their potential role as selective anti-thrombotic agents 
that would have limited impact on normal hemostasis.  
 Factor XI is probably the least well understood of all of the plasma proteases 
required for normal blood coagulation. The work in this thesis provides a foundation for 
future studies to delineate the role of this enzyme in vascular biology, and for efforts to 
develop therapeutic agents to treat or prevent human disease. 
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